All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-000149-39 | 'Phase III Randomized Trial to Evaluate the Efficacy and Safety of Second-line Therapy with Fludara plus Alentuzumab (CAMPATH, MabCampth) versus Fludara Alone in patients with B-Cell Chronic Lymphocyt... | 2010-06-18 | due-trials |
| Reported results | 2004-000555-42 | A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accum... | 2010-09-01 | due-trials |
| Reported results | 2004-000572-14 | PHASE II MULTICENTER, OPEN LABEL, NON RANDOMIZED STUDY OF INTRAVENOUS RPR109881 Q 3 WEEKS IN PATIENTS WITH METASTATIC BREAST CANCER PROGRESSING AFTER THERAPY WITH ANTHRACYCLINES, TAXANES AND CAPECITAB... | 2009-04-17 | due-trials |
| Reported results | 2004-000616-70 | Efficacy and safety of insulin glulisine compared with insulin lispro in children and adolescents with type 1 diabetes mellitus: a 26-week, multicenter, open, parallel clinical trial | 2007-02-05 | due-trials |
| Reported results | 2004-000618-38 | A randomized, open-label, phase III study of RPR109881 IV every 3 weeks versus capecitabine (Xeloda®) tablets twice daily for 2 weeks in 3-week cycles in patients with metastatic breast cancer progres... | 2010-05-10 | due-trials |
| Reported results Terminated | 2004-000738-34 | Multinational, randomized, double-blind, double-dummy, comparative study to evaluate the efficacy and safety of telithromycin 25 mg/kg given once daily for 5 or 10 days depending on age and previous t... | 2007-09-03 | due-trials |
| Reported results | 2004-000763-98 | A phase II, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HP184 at 100, 200 and 400 mg doses administered orally once daily for twenty-four weeks in adult su... | 2005-12-31 | due-trials |
| Reported results | 2004-000822-58 | A double blind randomized study of Clopidogrel 75 mg/d versus placebo on a background of ASA 75-100 mg/d, in peripheral arterial disease (PAD) patients receiving a unilateral below knee by-pass graft | 2009-08-05 | due-trials |
| Reported results | 2004-000851-41 | A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter study evaluating the efficacy and safety of four doses of SR147778 in obese patients | 2005-11-15 | due-trials |
| Reported results | 2004-000904-41 | A multinational, randomized, double-blind, double-dummy, exploratory, parallel-group, dose-ranging phase II study to evaluate the pharmacodynamics, the safety and tolerability, and the pharmacokinetic... | 2005-10-19 | due-trials |
| Completed, but no date, and reported results | 2004-001044-72 | Randomized phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer. | bad-data | |
| Reported results | 2004-001287-49 | 52-week, open, randomized, multinational, multicenter clinical trial comparing insulin glulisine in combination with insulin glargine in an intensified insulin regimen to a two-injection conventional ... | 2008-01-01 | due-trials |
| Reported results | 2004-001330-16 | Estudio de Fase II, aleatorizado, multicéntrico, doble ciego y controlado con placebo, del efecto de SR57667B sobre la función dopaminérgica nigro-estriada, evaluado mediante imágenes PET 18F-Dopa en ... | 2007-03-05 | due-trials |
| Reported results | 2004-001412-30 | An open-label, randomized, multicenter, clinical study to compare the effects of telithromycin, azithromycin and cefuroxime axetil on the penicillin or macrolide resistance of Streptococcus pneumoniae... | 2006-05-20 | due-trials |
| Reported results | 2004-001677-26 | Nolpitantium Besylate In patients with mild to moderate Ulcerative Colitis: a double-blind, placebo-controlled Efficacy and safety, 8-week study. | 2006-09-21 | due-trials |
| Reported results | 2004-001682-17 | A Randomized Dose Ranging Study of Hexadecasaccharide including Active Control, in Patients with Unstable Angina or Non-ST-segment Elevation Myocardial Infarction Scheduled to Undergo Percutaneous Cor... | 2007-05-21 | due-trials |
| Reported results | 2004-001766-40 | Placebo controlled double blind dose ranging study of the efficacy and safety of SSR149744C 50, 100, 200 or 300 mg OD, with amiodarone as calibrator for the maintenance of sinus rhythm in patients wit... | 2006-05-11 | due-trials |
| Trial is partly outside EEC, and reported results | 2004-001841-14 | Dose-ranging pharmacodynamic assessment of platelet aggregation inhibition with clopidogrel in children of Blalock-Taussig shunt age categories (neonates and infants/toddlers) | bad-data | |
| Completed, but no date, and reported results | 2004-001967-24 | Kiegészítő zolpidem kezelés friss antidepresszáns kezelés alatt álló disztimiás vagy depressziós betegek alvászavarának kezelésében | bad-data | |
| Reported results | 2004-002017-37 | Phase III randomized trial of concomitant radiation, cisplatin, and tirapazamine (SR259075) versus concomitant radiation and cisplatin in patients with advanced head and neck cancer | 2008-01-16 | due-trials |
| Reported results | 2004-002036-25 | Comparison of three therapeutic strategies for treating type 2 diabetes mellitus patients poorly controlled with basal insulin associated with oral antidiabetic drugs OSIRIS STUDY: Opposing Step-by-... | 2008-12-01 | due-trials |
| Completed, but no date, and reported results | 2004-002168-59 | An Open-Label, Multicenter, Multinational, Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Acid alpha- Glucosidase (rhGAA) Treatment in Patients > 6 and <= 3... | bad-data | |
| Completed, but no date, and reported results Terminated | 2004-002173-23 | PHASE 2 CLINICAL STUDY PROTOCOL: SAFETY AND EFFICACY OF RISING DOSES OF DEFERITRIN IN BETA-THALASSEMIA PATIENTS | bad-data | |
| Reported results | 2004-002174-32 | An Open Label, Randomized, Parallel Design Study to Investigate the Efficacy and Safety of Sevelamer Hydrochloride Renagel Compared with Calcium Acetate in Peritoneal Dialysis Patients | 2006-04-27 | due-trials |
| Reported results | 2004-002203-32 | A MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE III TRIAL COMPARING IMMEDIATE ADJUVANT HORMONAL THERAPY ELIGARD LEURPOLIDE ACETATE IN COMBINATION WITH TAXOTERE DOCETAXEL ADMINISTERED EVERY THREE WE... | 2010-12-17 | due-trials |
| Reported results | 2004-002317-37 | OPEN-LABEL STUDY TO DETERMINE HOW PRIOR THERAPY WITH ALENDRONATE OR RISEDRONATE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS INFLUENCES THE CLINICAL EFFECTIVENESS OF TERIPARATIDE | 2007-04-17 | due-trials |
| Reported results | 2004-002327-41 | an eight-week, multicenter, double-blind, placebo-controlled study evaluating the efficacy, safety and tolerability of one fixed 100 mg dose of Saredutant in patients with Major Depressive Disorder | 2006-12-29 | due-trials |
| Reported results | 2004-002328-16 | An eight-week, multicenter, double-blind, placebo-controlled study evaluating the efficacy, safety and tolerability of one fixed 100 mg dose of Saredutant in patients with Major Depressive Disorder | 2006-12-26 | due-trials |
| Reported results | 2004-002349-11 | A randomisation, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy and safety of SR121463B in patients with syndrome of inappropriate antidiuretic hormone sec... | 2007-09-27 | due-trials |
| Completed, but no date, and reported results | 2004-002390-23 | Evaluation of the pharmacokinetic profile of Riluzole (XRP4274) and RPR112512 following multiple oral administrations of XRP4274 for 8 days in healthy Japanese and Caucasian male subjects | bad-data | |
| Reported results | 2004-002397-38 | 12-week, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy, pharmacodynamic and safety of two doses of alfuzosin (0.1 mg/kg/day; 0.2 mg/kg/day... | 2009-12-16 | due-trials |
| Reported results | 2004-002508-13 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-Selection Study of Ad2/Hypoxia Inducible Factor HIF-1alfa/VP16 in Patients with Intermittent Claudication. | 2010-03-11 | due-trials |
| Completed, but no date, and reported results | 2004-002729-34 | PILOT STUDY FOR THE EVALUATION OF THE EFFECTS OF INSULIN TREATMENT ON MYOCARDIAL FUNCTION, PERFUSION, AND GLUCOSE METABOLISM IN PATIENTS WITH PRIMARY LEFT VENTRICULAR DYSFUNCTION AND TYPE 2 DIABETES | bad-data | |
| Completed, but no date, and reported results | 2004-002730-19 | see above | bad-data | |
| Completed, but no date, and reported results | 2004-002731-62 | OPTIMISATION OF INSULIN TREATMENT OF TYPE 2 DIABETES MELLITUS BY TELECARE ASSISTANCE FOR SELF MONITORING OF BLOOD GLUCOSE ELEONOR STUDY | bad-data | |
| Completed, but no date, and reported results Terminated | 2004-003809-25 | Comparison of the efficacy and tolerability of drotaverine 80 mg or ibuprofen 400 mg administered alone with their combination for the treatment of primary and secondary dysmenorrhea | bad-data | |
| Reported results | 2004-003885-14 | Multidisciplinar, multicenter, randomized phase III clinical trial comparing taxotere plus estramustine phosphate plus prednisone, versus taxotere prednisone, in advanced prostate carcinoma patients w... | 2009-07-18 | due-trials |
| Reported results | 2004-003929-27 | Randomized, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20-mg od, for inhibition of astherosclerosis progression assessed by IVUS (IntraVascular UltraSoun... | 2007-10-19 | due-trials |
| Reported results | 2004-003985-14 | A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of Two Doses of a Vasopressin V2 Receptor Antagonist (SR121463B) on Serum Sodium in Patients with Dilutional Hyp... | 2007-07-18 | due-trials |
| Completed, but no date, and reported results | 2004-004461-15 | SOLIAN solution in the acute setting | bad-data | |
| Reported results | 2004-004676-37 | A randomized, double-blind study of GT267-004 versus vancomycin, and GT267-004 versus metronidazole, in patients with C.difficile-associated diarrhea | 2007-08-08 | due-trials |
| Reported results | 2004-004799-35 | Double blind placebo controlled dose ranging study of the efficacy and safety of SSR149744C 100 or 300 mg for the prevention of ventricular arrhythmia-triggered ICD interventions | 2007-02-23 | due-trials |
| Reported results | 2004-004881-34 | A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve patients with type 2 dia... | 2006-06-09 | due-trials |
| Reported results | 2004-005239-25 | An open-label, multicenter study evaluating the long-term safety and efficacy of SR121463B in patients with Syndrome of Inappropriate Antidiuretic Hormone Secretion. | 2007-08-28 | due-trials |
| Reported results | 2004-005261-38 | A Multicenter, Parallel, Double-Blind, Blinded Evaluator, Randomized Comparison of the Efficacy and Safety of an Alternate Viscosupplement (AVS-beta) to Methylprednisolone Acetate in Patients with Sym... | 2007-09-19 | due-trials |
| Reported results | 2005-000577-21 | Estudio abierto y multicéntrico, de cincuenta y dos semanas de duración, para evaluar la seguridad y tolerabilidad a largo plazo de SR58611A 350 mg cada 12 horas en pacientes con trastorno depresivo ... | 2007-07-18 | due-trials |
| Reported results | 2005-000715-98 | A placebo-controlled, double blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with At... | 2008-04-21 | due-trials |
| Reported results | 2005-000807-33 | A randomized, double blind, two-arms placebo-controlled, parallel group, multicenter study of rimonabant 20 mg once daily in the treatment of atherogenic dyslipidemia in abdominally obese patients | 2007-04-19 | due-trials |
| Reported results | 2005-000823-40 | Double blind placebo controlled dose ranging study of the efficacy and safety of SSR149744C 300 or 600 mg for the conversion of atrial fibrillation/flutter | 2006-04-21 | due-trials |
| Reported results | 2005-000959-15 | A multicenter clinical trial to evaluate quality of life in patients with Type 2 diabetes before and after changing therapy to a combination of insulin glargine and oral antidiabetic drugs in a real l... | 2008-06-26 | due-trials |
| Reported results | 2005-001612-49 | Ensayo aleatorizado, multicéntrico, doble ciego, controlado con placebo y con dos grupos paralelos, de rimonabant 20 mg od, para la inhibición de la progresión de la aterosclerosis evaluada mediante e... | 2009-04-27 | due-trials |
| Reported results | 2005-001613-17 | A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Fixed- Dose Study Evaluating the Effect of One Dose of Rimonabant 20 mg/day on Glycemic Control in Type 2 Diabetic Patien... | 2007-07-30 | due-trials |
| Reported results | 2005-001629-27 | A Long-term Continuation Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602 | 2006-06-12 | due-trials |
| Reported results | 2005-001873-91 | Docetaxel (Taxotere) v léčbě hormonálně independentního karcinomu prostaty. | 2007-11-15 | due-trials |
| Reported results | 2005-002161-36 | RANDOMIZED COMPARISON OF A TWO-MONTH REGIMEN OF IRBESARTAN VERSUS ENALAPRIL ON CARDIOVASCULAR MARKERS IN PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT ST SEGMENT ELEVATION. | 2007-03-23 | due-trials |
| Completed, but no date, and reported results | 2005-002175-32 | Take evaluation and safety of smallpox vaccine (LISTER strain) in naïve healthy adults | bad-data | |
| Reported results | 2005-002401-23 | Immunogenicity of the Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Comparison with Intramuscular Vaccination with Vaxigrip® in Adults. | 2008-07-02 | due-trials |
| Reported results | 2005-002568-27 | A randomized, double blind, two-arm placebo controlled, 12-Month study of the effects of rimonabant 20mg once daily on the amount and the activity of visceral fat in abdominally obese patients with me... | 2008-07-24 | due-trials |
| Reported results | 2005-002570-30 | A multicenter randomized, double-blind placebo controlled phase III study of the efficacy of Xaliproden in preventing the neurotoxicity of oxaliplatin in first-line treatment of patients with metastat... | 2009-10-30 | due-trials |
| Reported results | 2005-002614-38 | COMPARISON OF TWO THERAPEUTIC STRATEGIES FOR TREATING TYPE 2 DIABETIC PATIENTS POORLY CONTROLLED WITH BASAL INSULIN ASSOCIATED WITH ORAL ANTIDIABETIC DRUGS: 6-MONTH PROOF OF CONCEPT STUDY | 2008-08-20 | due-trials |
| Reported results | 2005-002759-42 | A Randomized, Double-Blind, Multicenter, Multinational, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Myozyme, Recombinant Human Acid alpha-Glucosidase (rhGAA), Treatment i... | 2007-08-29 | due-trials |
| Reported results | 2005-002829-31 | Full title of the trial : A Single Centre, Open-Label, Bridging Study of the Safety, Pharmacokinetics and Efficacy of Recombinant Human Acid Alpha-Glucosidase (rhGAA) Treatment in Patients with Late-O... | 2006-07-13 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2005-002942-20 | Ensayo aleatorizado, multinacional, multicéntrico, doble ciego, controlado con placebo, con dos grupos paralelos, de rimonabant 20 mg od, para la reducción del riesgo de acontecimientos cardiovascular... | 2009-04-29 | bad-data |
| Reported results Terminated | 2005-002958-21 | The determination of the exact time of administration of Lantus basal insulin for treating type 2 diabetes mellitus patients poorly controlled with basal insulin associated with oral antidiabetic drug... | 2008-06-20 | due-trials |
| Exempt, with results | 2005-002965-35 | Safety of the Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Healthy Children | not-yet-due | |
| Reported results | 2005-003080-23 | Efficacy and safety of eplivanserin 5mg/day on sleep maintenance insomnia: a 12-week multicenter, randomized, double-blind, placebo-controlled study | 2008-01-10 | due-trials |
| Reported results | 2005-003082-16 | Efficacy and safety of eplivanserin 5mg/day on Sleep Maintenance Insomnia : a 12-week multicenter, randomized, double-blind, placebo-controlled study followed by an open treatment phase extension wi... | 2008-09-10 | due-trials |
| Reported results | 2005-003119-62 | Double-blind, double-dummy, randomized, parallel group trial of SL650472 (three dose regimens versus placebo and cilostazol), for 24-week improvement of walking distance in patients with stage II peri... | 2008-12-03 | due-trials |
| Completed, but no date, and reported results | 2005-003180-23 | An 8-week, double blind, placebo-controlled, multicenter study with paroxetine (20 mg q24) as positive control, evaluating the efficacy and safety of 2 fixed doses of SR58611A (175 mg q12 and 350 mg q... | bad-data | |
| Reported results | 2005-003181-41 | An eight-week, double-blind, placebo-controlled, multicenter study with paroxetine (20 mg q24) as positive control, evaluating the efficacy, safety and tolerability of a fixed dose of SR58611A (350 mg... | 2007-01-18 | due-trials |
| Reported results | 2005-003233-41 | An open label, dose titration study of sevelamer carbonate tablets dosed three times a day in hyperphosphatemic chronic kidney disease patients not on dialysis | 2007-03-31 | due-trials |
| Reported results | 2005-003258-87 | Efficacy and safety of intra-articular multiple doses of 500 mcg icatibant including 40 mg triamcinolone as calibrator in a randomized, double-blind, parallel-group, placebo-controlled 13-week multi-c... | 2007-07-31 | due-trials |
| Reported results | 2005-003449-15 | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ISIS 301012 as Add-on Therapy in Homozygous Familial Hypercholesterolemia Subjects | 2009-03-20 | due-trials |
| Reported results | 2005-003450-10 | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 301012 in Patients with Familial Hypercholesterolemia or Severe Hypercholesterolemia | 2009-12-17 | due-trials |
| Reported results | 2005-003521-13 | Double-blind, randomized, parallel-group, dose ranging, multi-center study to evaluate the efficacy and safety of 2.5, 10, 35 and 50 mg AVE7688 once daily, using 100 mg losartan-potassium once daily a... | 2008-04-03 | due-trials |
| Reported results | 2005-003765-17 | Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses Of BIKEN Acellular Pertussis Vaccine in Combination with Diphtheria and Tetanus Toxoids (Tripedia®)... | 2007-10-01 | due-trials |
| Reported results | 2005-003819-71 | A double-blind, placebo-controlled study followed by a repeat dosing phase to assess the efficacy and safety of DX-88 recombinant plasma kallikrein inhibitor for the treatment of acute attacks of ... | 2007-09-21 | due-trials |
| Reported results | 2005-004006-81 | A double-blind, 6 to 12-month, multicenter, multinational, randomized study evaluating the efficacy and safety of SR58611A (350 mg q12) versus placebo in the prevention of relapse / recurrence of depr... | 2008-02-01 | due-trials |
| Completed, but no date, and reported results Terminated | 2005-004034-41 | Evaluation of Skeletal Myoblast Transplant for Treating Ischemic Heart Failure Phase 2 Study Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Study | bad-data | |
| Reported results | 2005-004068-21 | A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study of Ad2/Hypoxia Inducible Factor (HIF)-1alfa/VP16 Administered by Intramuscular Injection to Patients with No ... | 2009-04-30 | due-trials |
| Reported results | 2005-004133-17 | A randomised, controlled, double blind study of the immunogenicity and safety of PEDIACEL®, a combined diphtheria, tetanus, five component acellular pertussis, inactivated poliomyelitis and Haemophilu... | 2007-05-28 | due-trials |
| Completed, but no date, and reported results | 2005-004450-27 | Follow-up of Thyroid Cancer Patients from Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method | bad-data | |
| Reported results | 2005-004451-35 | Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multin... | 2011-07-29 | due-trials |
| Completed, but no date, and reported results | 2005-004934-42 | Efficacy evaluation of Enterogermina, 2 billion Bacillus clausii spores, on eradication of small intestinal bacterial overgrowth a randomised, parallel-group, open study | bad-data | |
| Reported results | 2005-005024-14 | A multicenter, randomized, double-blind, parallel-arm, two-stage study of the efficacy and safety of AVE0005 (VEGF Trap) administered intravenously every 2 weeks in patients with platinum-resistant an... | 2010-03-29 | due-trials |
| Reported results | 2005-005026-31 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Effect of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients with Rec... | 2009-10-03 | due-trials |
| Reported results | 2005-005074-69 | Phase II Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Alemtuzumab (CAMPATH, MabCampath) in Patients with Previously Treated B Cell Chronic Lymphocytic Leukemia | 2011-08-19 | due-trials |
| Listed as ongoing, but also has a completion date | 2005-005077-29 | An International, Phase II, Randomized, Double-Blinded, Placebo- Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 ZACTIMA versus Placebo in Subjects with Unresectable Locally Advan... | 2015-11-23 | bad-data |
| Reported results | 2005-005141-19 | A 12-week, multicenter, double blind, placebo-controlled, randomized study of the efficacy and safety of 1.0 mg AVE8134 tablets for reducing A1c in the treatment of patients with confirmed type 2 diab... | 2007-05-15 | due-trials |
| Reported results | 2005-005149-20 | Tratamiento neoadyudante con quimioterapia (CapeOxa) y quimioradioterapia (CapeOxa/RT) seguida de cirugía versus quimioradioterapia seguida de cirugía y quimioterapia, en pacientes con cáncer de recto... | 2010-11-30 | due-trials |
| Reported results | 2005-005326-30 | International, multicenter, randomized, parallel group, double-blind study, in patients with acute symptomatic deep vein thrombosis of the lower limbs, demonstrating the bioequipotency at steady state... | 2008-02-01 | due-trials |
| Reported results | 2005-005464-92 | A RANDOMIZED PHASE II STUDY OF DOCETAXEL IN COMBINATION WITH OXALIPLATIN WITH OR WITHOUT 5-FU OR CAPECITABINE IN METASTATIC OR LOCALLY RECURRENT GASTRIC CANCER PREVIOUSLY UNTREATED WITH CHEMOTHERAP... | 2010-04-28 | due-trials |
| Reported results | 2005-005478-66 | Effect of a single oral 120 µg dose of SSR150106XB compared to placebo on the assessment of post dental surgical pain after extraction of an impacted or partially impacted third molar in 90 male and f... | 2006-08-10 | due-trials |
| Completed, but no date, and reported results Terminated | 2005-005481-36 | Alfuzosin in Uretheric Stones | bad-data | |
| Reported results | 2005-005532-27 | Comparison of Pertussis Specific Cellular and Humoral Immunity Before and After a Acellular Pertussis Booster-Vaccineation in Combination With a Diphtheria-Tetanus-Polio-Vaccine Between Three Groups o... | 2006-10-31 | due-trials |
| Reported results | 2005-005597-67 | An eight-week, double-blind placebo controlled, multicenter study evaluating the efficacy, safety, tolerability of a fixed dose of SR58611A (350 mg q12) in elderly patients with Major Depressive Disor... | 2007-08-21 | due-trials |
| Reported results | 2005-005598-30 | A NON-INVASIVE EVALUATION OF BONE MICROARCHITECTURE MODIFICATION IN OSTEOPENIC POSTMENOPAUSAL WOMEN BY 3D-PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY : A 24-MONTH, MONOCENTER, DOUBLE-BLIND, RANDOMIZED... | 2009-06-22 | due-trials |
| Reported results | 2005-005763-28 | Estudio aleatorizado, doble ciego, en el que se comparan los efectos de un régimen de clopidogrel durante 3 meses en combinación con AAS durante el primer mes, frente a AAS en monoterapia, para el tra... | 2013-07-20 | due-trials |
| Reported results | 2005-006202-26 | A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel group, Dose Response Study of subcutaneous AVE5026 with an Enoxaparin Calibrator Arm in the Prevention of Venous Thromboembolism in Pati... | 2007-06-18 | due-trials |
| Reported results | 2006-000122-31 | Srovnání fluktuací glykemií při bazální substituci humánním inzulínem NPH a inzulínovým analogem glargine (kontinuální měření glykemií) | 2007-11-27 | due-trials |
| Reported results | 2006-000132-27 | Estudio de Satavaptan en el Tratamiento de Ascitis Cirrótica: comparación doble ciego, aleatorizada, y con grupos paralelos del tratamiento con satavaptan de 5 a 10 mg diarios frente a placebo añadido... | 2008-12-30 | due-trials |
| Reported results | 2006-000134-12 | Satavaptan en la Prevención de la Recurrencia de Ascitis: comparación doble ciego, aleatorizada, y con grupos paralelos de satavaptan de 5 a 10 mg diarios frente a placebo con diuréticos concomitantes... | 2008-10-09 | due-trials |
| Reported results | 2006-000135-10 | Satavaptan en la Prevención de la Recurrencia de Ascitis: comparación doble ciego, aleatorizada, y con grupos paralelos de satavaptan de 5 a 10 mg diarios frente a placebo en asuncia de diuréticos en ... | 2009-03-03 | due-trials |
| Reported results | 2006-000152-41 | A multicenter, Randomized, Double Blind, Double Dummy, Parallel Group, Dose Ranging Study of subcutaneous SR123781A with an Enoxaparin calibrator arm in the Prevention of Venous Thromboembolism in Pat... | 2007-05-02 | due-trials |
| Reported results | 2006-000313-38 | Randomized, multinational, double-blind study, comparing a high loading dose regimen of clopidogrel versus standard dose in patients with unstable angina or myocardial infarction managed with an early... | 2010-12-31 | due-trials |
| Reported results | 2006-000324-13 | ESTUDIO MULTICÉNTRICO, INTERNACIONAL, ALEATORIZADO, ABIERTO, COMPARATIVO Y DE GRUPOS PARALELOS: OBJETIVOS DEL CONTROL GLUCÉMICO E INCIDENCIA DE HIPOGLUCEMIA SINTOMÁTICA COMPROBADA EN PACIENTES CON DIA... | 2008-06-12 | due-trials |
| Reported results | 2006-000477-29 | Safety and immunogenicity of an intramuscular, inactivated, split-virion, pandemic influenza A/H5N1 vaccine in adults and the elderly. | 2008-12-23 | due-trials |
| Reported results | 2006-000506-22 | A randomized, double-blind, triple-dummy, dose-ranging study, including an active control of unfractionated heparin and eptifibatide, to evaluate the clinical efficacy and safety of otamixaban, in pat... | 2009-03-01 | due-trials |
| Reported results | 2006-000604-16 | A Multicenter, Open-Label, Single-Arm Study of Intravenous AVE0005 VEGF Trap Administered Every 2 Weeks in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites | 2008-11-06 | due-trials |
| Reported results | 2006-000671-15 | Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2006-2007 Formulation (Intramuscular Route) | 2006-08-09 | due-trials |
| Completed, but no date, and reported results | 2006-000715-19 | A Long-Term Safety and Immunogenicity Follow-up of Healthy Adults Vaccinated with One Dose of Smallpox Vaccine (LISTER Strain). | bad-data | |
| Reported results | 2006-000763-29 | Pharmacokinetics, pharmacodynamics and safety of intra-articular multiple doses of 500 mcg icatibant in an uncontrolled 13-week multi-center study in patients with symptomatic knee osteoarthritis | 2006-10-31 | due-trials |
| Reported results | 2006-000898-30 | Safety and Immunogenicity of Booster Vaccination with PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjuga... | 2007-09-17 | due-trials |
| Trial is partly outside EEC, and reported results | 2006-000946-38 | International randomized double blind clinical study evaluating the efficacy and safety of clopidogrel 0.2mg/kg once daily versus placebo in neonates and infants with cyanotic congenital heart disea... | 2010-02-01 | bad-data |
| Trial is outside EEC, and reported results | 2006-001095-21 | Immunogenicity and Safety of PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus influenzae Type b Conjugate Vaccine (Adsorbed), Co... | bad-data | |
| Reported results | 2006-001099-20 | An international, seven-week, double blind, placebo-controlled, two parallel group study to assess the efficacy of dianicline 40 mg bid as an aid to smoking cessation in cigarette smokers | 2007-10-23 | due-trials |
| Reported results | 2006-001152-12 | An international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 14 m... | 2017-02-07 | due-trials |
| Completed, but no date | 2006-001248-30 | A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 μg administered either in a once-dai... | bad-data | |
| Reported results | 2006-001341-34 | Open label, uncontrolled study of XRP9881 in combination with trastuzumab (Herceptin®) in patients with HER2 positive metastatic breast cancer (MBC) | 2011-01-24 | due-trials |
| Reported results | 2006-001711-30 | A Pan-European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with impaired fasting... | 2009-04-02 | due-trials |
| Reported results | 2006-001715-30 | A European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with dyslipidemia with or... | 2009-01-30 | due-trials |
| Reported results | 2006-001716-71 | A RANDOMIZED, DOUBLE BLIND, TWO ARM, PARALLEL, PLACEBO CONTROLLED STUDY OF RIMONABANT 20MG EFFECT ON HIGH DENSITY LIPOPROTEIN KINETICS IN PATIENTS WITH ABDOMINAL OBESITY AND ADDITIONAL CARDIOMETABOLIC... | 2008-12-18 | due-trials |
| Reported results | 2006-001786-42 | An international, multicenter, randomized, double-blind, double-dummy, parallel group, study of 3-month or 6-month treatment with SSR126517E 3.0 mg s.c. once weekly versus oral INR-adjusted warfarin... | 2010-11-10 | due-trials |
| Reported results | 2006-001843-74 | A randomized, double-blind, parallel-group, placebo-controlled, dose-response, multicentre, multinational study evaluating the efficacy and safety of AVE2268 administered either twice daily breakfast... | 2008-01-07 | due-trials |
| Other | 2006-001910-33 | A Multicenter, Multinational Study of the Effects of Fabrazyme® (agalsidase beta) Treatment on Lactation and Infants | not-yet-due | |
| Reported results | 2006-002253-71 | A double-blind, multi-center, randomized withdrawal study evaluating the efficacy and safety of Amibegron 350 mg twice a day versus placebo in the prevention of relapse of anxiety up to 1 year in pa... | 2007-12-09 | due-trials |
| Reported results | 2006-002317-12 | A double-blind placebo-controlled study of the activity of AVE1625 at doses of 10 mg and 40mg for 12 weeks in patients with mild to moderate Alzheimer s Disease | 2007-07-12 | due-trials |
| Reported results | 2006-002366-18 | Immunogenicity of the Investigational Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip in the Elderl... | 2009-06-16 | due-trials |
| Reported results | 2006-002369-37 | Estudio sobre la consistencia lote a lote de la vacuna en investigación contra la gripe de virión fraccionado inactivado administrada por vía intradérmica en adultos | 2007-06-06 | due-trials |
| Completed, but no date, and reported results | 2006-002482-39 | Evaluation of the effects of Enterogermina, 2 billion Bacillus clausii spores, on the intestinal flora of children antibiotic treated for bacterial upper respiratory tract infections open, pilot stud... | bad-data | |
| Completed, but no date, and reported results Terminated | 2006-002847-96 | A 13-week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability and Efficacy of AVE0010 in Metformin-Treated Subjects with Type 2 Diabetes... | bad-data | |
| Reported results | 2006-002951-33 | A 12-month multicentre, randomised, double-blind, placebo-controlled study with two parallel groups to assess the effects of rimonabant 20 mg in patients with abdominal obesity and microalbuminuria, w... | 2009-01-29 | due-trials |
| Exempt, with results | 2006-003085-34 | A Dose-escalating, Multicenter, Single arm, Open-label Study of XRP6258 in combination with capecitabine (Xeloda®), in patients with metastatic breast cancer with disease progressing after anthracycli... | 2009-03-31 | not-yet-due |
| Reported results | 2006-003086-14 | A Randomized, Open Label Multi-Center Study of Single Agent Larotaxel XRP9881 at 90 mg/m2 every 3 weeks Compared to Continuous Administration of 5-FU For The Treatment of Patients With Advanced Panc... | 2009-12-23 | due-trials |
| Reported results | 2006-003087-59 | A Randomized, Open Label Multi-Center Study of XRP6258 At 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared To Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Ref... | 2009-09-25 | due-trials |
| Reported results | 2006-003134-14 | A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide fo... | 2010-04-07 | due-trials |
| Reported results | 2006-003138-13 | A randomized, double-blind, placebo-controlled, multinational study evaluating the safety and pharmacokinetics of 5 and 10 µg AVE0010 single doses and the efficacy, safety and pharmacokinetics of AVE0... | 2007-09-17 | due-trials |
| Reported results | 2006-003361-14 | Long-term extension of the multinational, double-blind, placebo controlled study EFC6049 HMR1726D/3001 to document the safety of two doses of teriflunomide 7 and 14 mg in patients with multiple sc... | 2015-12-23 | due-trials |
| Reported results | 2006-003644-31 | An Open-Label Extension Study of Patients with Late-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU02704 | 2008-11-13 | due-trials |
| Reported results | 2006-003793-94 | An Eight-Week, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Study, with Escitalopram as an Active Control, to Evaluate the Efficacy, Safety and Tolerability of a Saredutant... | 2008-07-21 | due-trials |
| Reported results | 2006-003805-19 | An eight-week, multinational, multicenter, randomized, double-blind, placebo-controlled study, with escitalopram as an active control, to evaluate the efficacy, safety and tolerability of a saredutant... | 2008-04-03 | due-trials |
| Completed, but no date, and reported results Terminated | 2006-003886-15 | Steady state telithromycin pharmacokinetics and pharmacodynamic in adult patients with mild-moderate acute exacerbation of chronic obstructive pulmonary disease treated with a standard oral dose 8... | bad-data | |
| Reported results | 2006-004146-16 | A multi-national, multi-center, double blind, placebo-controlled, parallel group, fixed dose efficacy and safety study of SR58611A 350 mg twice daily vs. placebo in adults with Major Depressive Disord... | 2008-02-22 | due-trials |
| Reported results | 2006-004147-33 | An Eight-Week, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Fixed Dose of SR58611A 350 mg Twice a Day in Elderly Patients with Generalized Anx... | 2007-09-14 | due-trials |
| Reported results | 2006-004247-29 | A Multicenter, Randomized, Comparative, Patient-blinded Study to Evaluate the Safety and Efficacy of G-CSF Alone Versus AMD3100 (240 µg/kg) Added to a G-CSF Mobilization Regimen in Adult Patients with... | 2009-06-23 | due-trials |
| Reported results | 2006-004275-35 | A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID ... | 2008-10-08 | due-trials |
| Completed, but no date, and reported results | 2006-004740-22 | A multicenter, multi-national, randomized, double-blind, placebo-controlled, study to assess the efficacy and safety of ciclesonide metered-dose inhaler at 80 μg BID or 40 μg BID for 12 weeks in patie... | bad-data | |
| Reported results | 2006-004756-20 | A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic ... | 2012-04-17 | due-trials |
| Reported results | 2006-004817-16 | A Prospective, Randomized, Open-Label, Parallel-Group, Multicenter Study to Demonstrate the Superiority of Matrix-induced Autologous Chondrocyte Implantation (MACI® implant) versus Arthroscopic Micro... | 2013-03-20 | due-trials |
| Completed, but no date, and reported results | 2006-004840-21 | Bone Histomorphometry, Microarchitecture and Matrix Structure and Properties in Patients Receiving Long-term Risedronate Treatment | bad-data | |
| Reported results | 2006-004893-29 | A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide fo... | 2010-06-09 | due-trials |
| Reported results | 2006-004942-18 | Efficacy and safety of 2 mg/day of M100907 on Sleep Maintenance Insomnia with a sub-study of the effect of M100907 on stable Type II Diabetes Mellitus a One Year, multi-center, randomized, double-bli... | 2009-03-11 | due-trials |
| Reported results | 2006-005303-34 | Efficacy and safety of 2 mg/day M100907 on Sleep Maintenance Insomnia: a 6-week, multicenter, randomized, double-blind, placebo-controlled Polysomnographic study | 2008-01-16 | due-trials |
| Reported results | 2006-005320-16 | Long-term Observational Follow-up Study of a Multicenter, Randomized, Double-blind, Placebo-controlled, Comparative Trial of AMD3100 (240 µg/kg) plus G-CSF (10 µg/kg) Versus G-CSF (10 µg/kg) plus Plac... | 2011-07-29 | due-trials |
| Reported results | 2006-005334-21 | A randomized, double-blind, placebo-controlled, parallel group, fixed-dose, 8-week treatment, multi-center trial evaluating the dose effect relationship for efficacy and the safety of 3 oral doses of ... | 2008-04-04 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2006-005385-39 | A Randomized, Double-Blind, Parallel-Group, Multicenter, Multinational Study to Assess Glycemic Control with Rimonabant in Comparison with Glimepiride over 1 Year in Overweight/Obese Type 2 Diabetic P... | 2009-03-04 | bad-data |
| Reported results | 2006-005422-23 | An open-label, multicenter study evaluating the long-term safety of satavaptan (SR121463B) and maintenance of normonatremia in patients with dilutional hyponatremia who have previously been treated in... | 2008-10-06 | due-trials |
| Reported results | 2006-005469-20 | A randomized, double-blind, parallel-group, placebo-controlled, ezetimibe-calibrated, multicenter study evaluating the safety and efficacy of four doses and two dose-regimens of AVE5530 over 4 weeks i... | 2007-10-26 | due-trials |
| Reported results | 2006-005753-29 | A single-blind, placebo-controlled, multicentre study evaluating continued long-term treatment with satavaptan (SR121463B) in patients with ascites due to liver cirrhosis who have previously been trea... | 2008-12-12 | due-trials |
| Reported results | 2006-005804-15 | Randomized double blind trial to evaluate the efficacy and safety of dronedarone (400 mg BID) versus amiodarone (600 mg daily for 28 days then 200 mg daily thereafter) for at least 6 months for the ma... | 2008-10-03 | due-trials |
| Completed, but no date, and reported results | 2006-005946-35 | Efficacy and safety of 3 intra-articular injections of 500 µg icatibant in a randomized, double-blind, parallel-group, placebo-controlled 13-week multi-centre study in patients with symptomatic knee o... | bad-data | |
| Exempt, with results | 2006-005978-51 | Uncontrolled, multicenter, dose finding, safety and pharmacokinetic study of AVE1642, an anti-Insulin-like Growth Factor-1 Receptor (IGF-1R/ CD221) monoclonal antibody, administered as single agent an... | 2009-12-21 | not-yet-due |
| Reported results | 2006-006144-55 | A multicenter, open-label, single-arm, two-stage study of the efficacy and safety of AVE0005 (VEGF Trap) administered intravenously every 2 weeks in patients with platinum- and erlotinib-resistant, lo... | 2008-07-18 | due-trials |
| Reported results | 2006-006152-34 | A Multicenter, Open-Label, Single Arm Study of Weekly Alvocidib in Patients with Previously Treated B-Cell Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) Arising from CLL | 2012-01-16 | due-trials |
| Reported results | 2006-006277-24 | A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF 4 ADMINISTRATIONS OF XRP0038/NV1FGF 4mg AT 2WEEK INTERVALS ON AMPUTATION OR ANY DEATH IN CRITICAL LIMB ... | 2012-08-08 | due-trials |
| Reported results | 2006-006473-24 | A randomized, open-label, multi-center study of larotaxel at 90mg/m² or docetaxel every 3 weeks, alone or in combination with trastuzumab according to Her2neu status, administered after a combination ... | 2010-03-31 | due-trials |
| Exempt, with results | 2006-006474-21 | A dose-escalating, multicenter, single arm, open-label study of XRP9881 in combination with capecitabine (Xeloda®), in metastatic breast cancer patients with disease progressing after anthracycline an... | 2009-03-16 | not-yet-due |
| Reported results | 2006-006521-30 | Long term safety and tolerability of satavaptan in patients with cirrhosis of the liver that have been previously randomized and completed treatment in any of the phase III studies: EFC4492; EFC4493 o... | 2009-01-10 | due-trials |
| Reported results | 2006-006677-25 | Efficacy and safety of 2mg/day of M100907 on Sleep Maintenance Insomnia with a sub-study of the effect of M100907 on stable Type II Diabetes Mellitus: a 12-week, multi-center, randomized, double-blind... | 2008-10-30 | due-trials |
| Reported results | 2007-000323-17 | A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation with Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects with a Rising PSA Following De... | 2012-10-05 | due-trials |
| Reported results | 2007-000582-37 | A Phase 4 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study of Colesevelam as Add-on Therapy in Patients with Familial Hypercholesterolaemia | 2009-10-22 | due-trials |
| Reported results | 2007-000752-14 | Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation (Intramuscular Route) | 2007-07-03 | due-trials |
| Reported results | 2007-000760-24 | Activity and safety of oral administration of SSR150106XB for the reduction of inflammation in patients with active rheumatoid arthritis (RA): A 4-week, multi-center, randomized, double-blind, placebo... | 2011-11-15 | due-trials |
| Reported results | 2007-000819-29 | A Multinational, Randomized, Double-Blind Study Comparing Aflibercept Versus Placebo in Patients Treated with Second-Line Docetaxel after Failure of One Platinum Based Therapy for Locally Advanced or ... | 2011-10-13 | due-trials |
| Reported results | 2007-000820-42 | A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients with Metastatic Colorectal Cancer (MCRC) Treated with Irinotecan /... | 2012-06-29 | due-trials |
| Reported results | 2007-000886-40 | Assessment of the early efficacy response rate of leflunomide according to the initial dosing regimen in the treatment of naive - DMARD early RA-patients. | 2009-10-16 | due-trials |
| Reported results | 2007-000945-36 | "A multicenter, randomized, double blind, placebo controlled Phase III study to assess the efficacy of xaliproden in patients with oxaliplatin-induced peripheral sensory neuropathy (PSN) following adj... | 2009-11-27 | due-trials |
| Reported results | 2007-000983-26 | 12-week, multicenter, open-label, non-comparative study to investigate pharmacodynamic and safety of alfuzosin 0.2 mg/kg/day in the treatment of children and adolescents 2 - 16 years of age with hydro... | 2009-10-09 | due-trials |
| Reported results | 2007-001043-22 | A Multicenter, Open-Label Study of Hectorol (doxercalciferol capsules) for the Treatment of Secondary Hyperparathyroidism in Stage 3 or Stage 4 Chronic Kidney Disease (CKD) Patients | 2013-07-20 | due-trials |
| Reported results | 2007-001161-14 | A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Relapsi... | 2011-05-13 | due-trials |
| Reported results | 2007-001162-32 | A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients... | 2011-09-15 | due-trials |
| Trial is outside EEC, and reported results | 2007-001163-30 | A trial of antigen-specific immune tolerance induction in mucopolysaccharidosis I (MPS I) patients initiating enzyme replacement therapy with Aldurazyme® (laronidase) | bad-data | |
| Trial is partly outside EEC, and reported results | 2007-001211-33 | International randomized study to evaluate the addition of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) vs. cisplatin-5-fluorouracil (CF) in the induction treatment of nasopharyngeal... | 2012-04-24 | bad-data |
| Reported results | 2007-001639-80 | A multicenter, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance and safety/tolerability of SSR180711C, at the doses of 2, 8 and 20 mg/d for 4 weeks, using ... | 2008-07-24 | due-trials |
| Reported results | 2007-001852-38 | A Multicenter, Open-Label, Randomized Study Comparing the Efficacy and Safety of S-1 as a Single Agent at 30 mg/m2 BID versus 5-FU Bolus Infusion for the Treatment of Patients with Metastatic Pancrea... | 2010-06-08 | due-trials |
| Reported results | 2007-001943-23 | Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced /Metastatic Urothelial Tract or Bladder Cancer | 2011-02-16 | due-trials |
| Completed, but no date, and reported results Terminated | 2007-002077-31 | Effects of Rimonabant on urinary albumin excretion rate on the components of the metabolic syndrome in patients with type 2 diabetes mellitus and microalbuminuria on background ramipril treatment. A p... | bad-data | |
| Reported results | 2007-002104-18 | Evaluation of the Cellular, Humoral and Mucosal Immune Response in Adults and Elderly Subjects Vaccinated either with an Inactivated Influenza Vaccine Administered via the Intradermal Route or an Inac... | 2008-05-05 | due-trials |
| Reported results | 2007-002172-34 | A double-blind, randomized, placebo-controlled, study evaluating the safety and activity of four escalating single doses of AVE0657 in congestive heart failure patients presenting as Cheyne-Stokes Bre... | 2009-03-30 | due-trials |
| Reported results | 2007-002174-58 | A double-blind, randomized, placebo-controlled, study of the safety and activity of four escalating single doses of AVE0657 in patients suffering from Obstructive Sleep Apnea Hypopnea Syndrome | 2009-01-19 | due-trials |
| Reported results | 2007-002492-14 | A randomized, double-blind, parallel-group, multicenter, multinational study to assess the long-term effect, over 1 year, of rimonabant 10 mg in comparison with rimonabant 20 mg after an initial treat... | 2009-02-27 | due-trials |
| Reported results | 2007-002532-28 | A Phase II Study of Efficacy of Rabbit Anti-thymocyte Globulin (rATG) in patients with Low and Itermediate-1 Risk Mylodysplastic Syndrome | 2009-07-03 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2007-003012-61 | A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of non-diabetic patients with nonalcoholic steatohepatitis (NASH) | 2009-02-27 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2007-003013-14 | A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of Type 2 diabetic patients with nonalcoholic steatohepatitis (NASH) | 2009-02-23 | bad-data |
| Reported results | 2007-003159-36 | An eight-week, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of saredutant 100 mg once daily in combination with escitalopram 10 mg once daily in patients w... | 2009-01-14 | due-trials |
| Completed, but no date, and reported results | 2007-003393-25 | None | bad-data | |
| Reported results | 2007-003476-19 | A Multinational, Randomized, Double-Blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer | 2010-11-26 | due-trials |
| Reported results | 2007-003579-38 | Efecto de la insulina glulisina en comparación con la insulina aspart y la insulina lispro cuando se administran mediante Infusión Subcutánea Continua de Insulina (ISCI) sobre parámetros específicos d... | 2009-06-15 | due-trials |
| Reported results | 2007-003592-39 | A multinational, randomized, double-blind placebo controlled study of AVE8062 (25 mg/m²) administered every 3 weeks in patients with advanced-stage soft tissue sarcoma, treated with cisplatin (75 mg/m... | 2013-04-17 | due-trials |
| Reported results | 2007-003822-28 | Comparison of the safety and efficacy of eplivanserin and lormetazepam in the treatment of insomnia characterized by sleep maintenance difficulties. A 4 week, randomized, double-blind, comparative, pa... | 2009-03-09 | due-trials |
| Reported results | 2007-003863-31 | An eight-week, double-blind study to evaluate the efficacy, safety, and tolerability of two fixed doses of saredutant (100 mg and 30 mg) once daily in combination with paroxetine 20 mg once daily comp... | 2009-02-27 | due-trials |
| Reported results | 2007-003885-16 | A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients... | 2009-09-08 | due-trials |
| Reported results | 2007-003997-24 | Long-term extension of the multinational, double-blind, placebo controlled study PDY6045 and PDY6046 to document the safety of teriflunomide when added to treatment with interferon-beta or glatiramer ... | 2010-04-30 | due-trials |
| Reported results | 2007-004126-24 | A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactiv... | 2009-02-07 | due-trials |
| Reported results | 2007-004452-36 | A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis | 2015-06-18 | due-trials |
| Reported results | 2007-004817-33 | A multicenter, randomized, double-blind, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous biotinylated idraparinux (SSR126517E) with oral adjusted-d... | 2010-11-01 | due-trials |
| Reported results | 2007-004833-40 | A randomized, double blind, placebo controlled study evaluating the glycemic effect of rimonabant added to metformin in patients with type 2 diabetes insufficiently controlled with metformin monothera... | 2009-02-18 | due-trials |
| Reported results | 2007-005668-28 | A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (agalsidase beta) in Treatment-Naive Male Pediatric Patients with Fabry Disease Without Severe Symptom... | 2015-06-22 | due-trials |
| Reported results | 2007-005772-13 | Comparative efficacy of amisulpride vs. risperidone on cognitive functions in patients with chronic schizophrenia. | 2010-01-15 | due-trials |
| Reported results | 2007-005880-80 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of metformin in patients with typ... | 2011-03-09 | due-trials |
| Reported results | 2007-005881-11 | A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of a sulfonylurea in patien... | 2011-01-14 | due-trials |
| Reported results | 2007-005883-28 | A randomized, open-label, active-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 versus exenatide on top of metformin ... | 2010-11-18 | due-trials |
| Reported results | 2007-005884-92 | A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy and safety of AVE0010 on top of pio... | 2011-06-29 | due-trials |
| Reported results | 2007-005886-36 | A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy and safety of AVE0010 in patients w... | 2011-02-08 | due-trials |
| Completed, but no date, and reported results | 2007-005887-29 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter 12-week study assessing the efficacy and safety of AVE0010 in patients with type 2 diabetes not treated with antidiabetic ag... | bad-data | |
| Reported results | 2007-006640-22 | Superioridad de insulina glargina Lantus frente a NPH: “Tratar hasta alcanzar la Normoglucemia”. Comparación del efecto de insulina glargina vs insulina NPH en pacientes con diabetes mellitus de tipo... | 2012-07-17 | due-trials |
| Ongoing, reported early | 2007-007003-33 | A Multicenter, Multinational, Open-Label Study of the Effects of Aldurazyme(laronidase) Treatment on Lactation in Women with Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants | not-yet-due | |
| Reported results | 2007-007941-10 | A Double-Blind, Randomized, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of two doses of Satavaptan (SR121463B) Versus Placebo in Patients with Dilutional Hyponatremia due t... | 2008-12-10 | due-trials |
| Reported results | 2007-007942-36 | A Multinational, Multicenter, Randomized, Double Blind Study comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdo... | 2010-08-12 | due-trials |
| Reported results | 2007-007943-29 | A multinational, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for... | 2010-11-18 | due-trials |
| Reported results | 2007-007944-80 | A Multinational, Multicenter, Randomized, Double-blind Study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Elective T... | 2009-06-30 | due-trials |
| Reported results | 2007-007945-11 | A Multinational, Multicenter, Randomized, Double-Blind study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Hip Fractu... | 2009-10-28 | due-trials |
| Reported results | 2007-007946-37 | A Multinational, Multicenter, Randomized, Double-blind Study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the prevention of Venous Thromboembolism in Patients Undergoing Elective K... | 2009-05-11 | due-trials |
| Reported results | 2007-007947-28 | A Multinational, Multicenter, Randomized, Double-Blind study Comparing the Efficacy and Safety of AVE5026 with placebo for the Extended Prevention of Venous Thromboembolism in Patients Having Undergon... | 2010-01-22 | due-trials |
| Reported results | 2008-000228-13 | A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Primary Prevention of Venous Thromboembolism in Acutely Ill Medical Pa... | 2009-03-16 | due-trials |
| Reported results | 2008-000516-32 | Estudio de superioridad de insulina glargina frente a sitagliptina en pacientes con diabetes tipo 2, sin experiencia previa de insulinoterapia, que reciben tratamiento con metformina y no están sufici... | 2011-07-21 | due-trials |
| Reported results | 2008-000521-19 | Combination therapy of insulin glargine and sitagliptin in patients with type 2 diabetes not adequately controlled by a previous treatment with metformin and either insulin glargine or sitagliptin (Ex... | 2011-09-13 | due-trials |
| Reported results | 2008-000689-21 | Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkins Lymphoma (NHL), Hodgkins Disease (HD) or Multiple My... | 2010-11-18 | due-trials |
| Reported results | 2008-000810-54 | Multicenter, randomized, open label study evaluating an anti Insulin-like Growth Factor-1 Receptor (IGF-1R/CD221) monoclonal antibody, AVE1642, administered every 4 weeks in combination with fulvestra... | 2010-11-10 | due-trials |
| Reported results | 2008-000943-33 | Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation (Intramuscular Route) | 2008-07-23 | due-trials |
| Reported results | 2008-001002-16 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter, 24-week study followed by an extension assessing the efficacy and safety of AVE0010 in two titration regimens on top of met... | 2011-09-16 | due-trials |
| Reported results | 2008-001043-19 | A Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine versus Cytarabine Alone in Adult Patients 55 Years and Older with Acute Myelogenous Leukemia (AML) who have ... | 2010-05-25 | due-trials |
| Reported results | 2008-001219-39 | Immunogenicity and Safety of the Investigational Inactivated, Split-Virion Influenza Vaccine 15 µg Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip... | 2008-06-20 | due-trials |
| Reported results | 2008-001492-30 | Comparación de la seguridad y eficacia de volinanserina y lormetazepam en el tratamiento del insomnio caracterizado por la dificultad para mantener el sueño. Estudio comparativo, aleatorizado, doble c... | 2009-01-30 | due-trials |
| Reported results | 2008-001518-26 | Efficacy and safety of oral ataciguat (HMR1766) 200 mg administered once daily for 28 days on pain reduction in patients with Neuropathic Pain. A randomized, double-blind, placebo-controlled, cross-ov... | 2009-09-10 | due-trials |
| Reported results | 2008-001550-41 | A multicenter, double-blind, randomized, 12-month, placebo-controlled study to evaluate the lipid-lowering effect, safety and tolerability of AVE5530 25 mg/day and 50mg/day when added to ongoing stabl... | 2009-06-17 | due-trials |
| Reported results | 2008-001718-26 | An eight-week, multicenter, randomized, double-blind, placebo-controlled dose-finding study, with escitalopram (10mg daily) as active control, to evaluate the efficacy, safety and tolerability of thre... | 2010-02-16 | due-trials |
| Reported results | 2008-001999-67 | A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients with Multiple Scl... | 2010-03-02 | due-trials |
| Completed, but no date Terminated | 2008-002500-26 | A multicenter, double blind, placebo controlled randomized study of the efficacy and safety of two rimonabant/metformin combinations for reducing A1C in the treatment of patients with type 2 diabetes ... | bad-data | |
| Reported results | 2008-002849-23 | A multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and tolerability of AVE5530 when added to ongoing stable statin therapy at high doses in patients wit... | 2009-06-11 | due-trials |
| Reported results | 2008-003284-39 | Etude nationale, multicentrique, non comparative, évaluant l’efficacité de l’association lévofloxacine (500 mg) et rifampicine (600 ou 900 mg selon le poids) administrée une fois par jour par voie ora... | 2010-04-23 | due-trials |
| Reported results | 2008-003375-41 | Etude de non-infériorité Bi-Profénid® 200 mg versus Bi-Profénid® 300 mg chez des patients présentant des douleurs liées à des affections aiguës bénignes fermées post-traumatiques de l'appareil locomot... | 2009-06-16 | due-trials |
| Reported results | 2008-003791-22 | Efficacy and safety of eplivanserin 5mg/day in insomnia characterized by sleep maintenance difficulties: a 6-week, randomized, double-blind, placebo-controlled, polysomnography study | 2009-06-05 | due-trials |
| Reported results | 2008-004178-41 | Estudio aleatorizado, multinacional de Aflibercept y FOLFOX6 modificado como tratamiento de primera línea para pacientes con cáncer colorrectal metastático | 2012-01-11 | due-trials |
| Reported results | 2008-004907-69 | A Phase II randomized, placebo-controlled, double-blind, dose ranging study of a Clostridium difficile toxoid vaccine (ACAM-CDIFF) in subjects with Clostridium difficile-associated infection(CDI) | 2011-07-11 | due-trials |
| Trial is partly outside EEC, and reported results | 2008-004999-53 | Estudio de seguridad a largo plazo en los pacientes incluidos en el estudio CLARINET con cardiopatía congénita cianosante paliada con derivación sistémica a la arteria pulmonar en los cuales persista ... | 2010-07-21 | bad-data |
| Reported results | 2008-005127-29 | MULTICENTER PHASE III RANDOMIZED TRIAL COMPARING DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY DOCETAXEL (AC->T) WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY DOCETAXEL AND TRASTUZUMAB (HERCEPTIN®)... | 2014-12-30 | due-trials |
| Reported results | 2008-005222-37 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 | 2016-01-21 | due-trials |
| Reported results | 2008-005223-28 | A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have been Stabi... | 2015-06-02 | due-trials |
| Reported results | 2008-005791-27 | Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in European Children | 2010-01-18 | due-trials |
| Reported results | 2008-006020-53 | A Prospective Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Re... | 2010-10-14 | due-trials |
| Reported results | 2008-006226-34 | A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis | 2015-05-13 | due-trials |
| Reported results | 2008-006796-80 | The QUTIE Study: A Randomized, Double-Blind, Placebo-controlled Study Comparing Aflibercept Versus Placebo on the QTc interval in Cancer Patients treated with Docetaxel | 2010-11-08 | due-trials |
| Reported results | 2008-007026-19 | COMPARISON OF A BASAL PLUS ONE INSULIN REGIMEN (INSULIN GLARGINE/INSULIN GLULISINE) WITH A BIPHASIC INSULIN REGIMEN (INSULIN ASPART/INSULIN ASPART PROTAMINE 30/70) IN TYPE 2 DIABETES PATIENTS FOLLOWIN... | 2012-12-20 | due-trials |
| Reported results | 2008-007334-22 | A randomized, double-blind, double-dummy, 2-arm parallel-group, multicenter 24-week study comparing the efficacy and safety of AVE0010 to sitagliptin as add-on to metformin in obese type 2 diabetic pa... | 2011-03-21 | due-trials |
| Reported results | 2008-007335-40 | A randomized, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week double-blind treatment period assessing the efficacy and safety of lixisenatide in patients with Type 2 diabet... | 2011-08-01 | due-trials |
| Reported results | 2008-008265-36 | ?Estudio aleatorizado, con doble enmascaramiento, controlado con placebo y de grupos paralelos de la eficacia y la seguridad de dos dosis de comprimidos para chupar de lisinato de ketoprofeno (6,25 mg... | 2010-04-27 | due-trials |
| Reported results | 2008-008412-47 | Double blind placebo controlled dose ranging study of the efficacy and safety of celivarone at 50, 100 or 300 mg OD with Amiodarone as calibrator for the prevention of ICD interventions or death | 2011-05-12 | due-trials |
| Reported results | 2009-009877-85 | Immunogenicity of the Purified Vero Rabies Vaccine – Serum Free in Comparison with the Reference Purified Vero Rabies Vaccine in Pre-exposure Use in Healthy Adults | 2011-02-14 | due-trials |
| Reported results | 2009-009936-56 | Randomized, double-blind, placebo and active controlled study of the activity of SAR407899A single-dose on the ability to increase duration of penile rigidity, under experimental condition, in patient... | 2009-10-26 | due-trials |
| Reported results | 2009-009977-85 | Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation (Intradermal Route) | 2009-06-18 | due-trials |
| Reported results | 2009-010339-42 | An eight-week, multinational, multicenter, double-blind, active- and placebo-controlled clinical trial evaluating the efficacy and tolerability of three fixed doses of SSR125543 (20 mg daily, 50 mg da... | 2011-03-14 | due-trials |
| Reported results | 2009-010788-18 | An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab | 2016-02-16 | due-trials |
| Reported results | 2009-010913-59 | Health Assessment, Patient treatment satisfaction and Quality-of-Life in insulin-naive type 2 diabetes Patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glarg... | 2012-10-16 | due-trials |
| Trial is partly outside EEC, and reported results | 2009-011231-12 | A 24-week, randomized, open-label, parallel group multinational comparison of Lantus® (insulin glargine) given in the morning as once-a-day basal insulin versus Neutral Protamine Hagedorn (NPH) insuli... | 2011-03-30 | bad-data |
| Reported results | 2009-012852-26 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate cardiovascular outcomes during treatment with lixisenatide in type 2 diabetic patients after an Acute Coro... | 2015-02-11 | due-trials |
| Reported results | 2009-013344-37 | Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-Origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Adult and Elderly s... | 2010-10-08 | due-trials |
| Completed, but no date, and reported results | 2009-013346-83 | Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 3 to ... | bad-data | |
| Reported results | 2009-013858-32 | Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 6 to ... | 2011-01-05 | due-trials |
| Reported results | 2009-015066-61 | Efficacy and safety of SAR407899A in patients with painful diabetic neuropathy. A 28-day, randomized, double-blind, placebo-controlled, parallel-group study. | 2013-07-20 | due-trials |
| Completed, but no date, and reported results | 2009-015742-34 | Better Accepance of a Singe injection Apidra (insulin glulisine) Added to once daily Lantus (insulin glargine) versus twice daily Premixed insulin in a real Life Use Setting. | bad-data | |
| Reported results | 2009-015811-42 | A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once Daily versus Twice Daily Dosing of Genz-112638 in Patients with G... | 2015-10-06 | due-trials |
| Reported results | 2009-016068-35 | A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS) | 2011-06-21 | due-trials |
| Reported results | 2009-016091-80 | Estudio multicentrico, randomizado, abierto, para evaluar el inhibidor de la poli (ADP-ribosa) polimerasa 1 (PARP-1), BSI-201, administrado una o dos veces por semana, en combinación con gemcitabina/c... | 2013-05-29 | due-trials |
| Reported results | 2009-016266-90 | A randomized, double-blind, placebo-controlled, multicenter, two-part, dose ranging and confirmatory study with an operationally seamless design, evaluating efficacy and safety of SAR153191 on top of ... | 2013-10-08 | due-trials |
| Reported results | 2009-016568-36 | Estudio aleatorizado, doble ciego y con triple simulación para comparar la eficacia de otamixabán con la de heparina no fraccionada más eptifibatida en pacientes con angina inestable/infarto de miocar... | 2013-05-07 | due-trials |
| Reported results | 2009-016707-30 | A Phase 2 Study of XL147 in Subjects with Advanced or Recurrent Endometrial Carcinoma | 2013-03-06 | due-trials |
| Reported results | 2009-016818-24 | A Randomized, international, multi-center, open-label study to document optimal timing of initiation of dronedarone TreatmEnt after conversion with loading dose of aMIodarone in patients with perSiste... | 2012-12-14 | due-trials |
| Reported results | 2009-016970-33 | An Extension Protocol for Participants of Genzyme-Sponsored Prospective, Randomized, Open-Label, Parallel-Group, Multicenter Study of Matrix-Induced Autologous Chondrocyte Implantation (MACI® implant)... | 2015-03-18 | due-trials |
| Reported results | 2009-017270-21 | Estudio aleatorizado de fase II de gemcitabina/cisplatino con o sin SAR240550 (BSI-201), un inhibidor de PARP1, en pacientes con cáncer de pulmón no microcítico en estadio IV _________________________... | 2011-12-12 | due-trials |
| Reported results | 2009-017666-23 | An open-label, randomized, two-arm parallel group study to compare the effects of 4-week QD treatment with lixisenatide or liraglutide on the postprandial plasma glucose in patients with type 2 diabet... | 2010-11-18 | due-trials |
| Completed, but no date, and reported results | 2009-017688-40 | Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intradermal Route) | bad-data | |
| Reported results | 2009-017690-38 | Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intramuscular Route) | 2010-05-27 | due-trials |
| Reported results | 2009-018172-33 | A 24-week, open, multicenter, comparative study of 2 strategies (including insulin glargine versus premixed insulin) for the therapeutic management of patients with type 2 diabetes failing oral agents | 2012-02-27 | due-trials |
| Reported results Terminated | 2009-018215-53 | The effect of the addition of dronedarone to, versus increase of, existing conventional rate control medication on ventricular rate during paroxysmal or persistent atrial fibrillation (AFRODITE study) | 2011-10-03 | due-trials |
| Reported results | 2010-018437-21 | A 24-week, multicenter, international, randomized (1:1), parallel-group, open-label, comparative study of insulin glargine versus liraglutide in insulin-naïve patients with Type 2 diabetes treated wit... | 2013-03-06 | due-trials |
| Reported results | 2010-018960-17 | "Estudio de fase II, abierto, aleatorizado para evaluar la eficacia y seguridad de paclitaxel administrado semanalmente como agente único y dos regímenes diferentes de SAR240550 (BSI-201), un inhibido... | 2017-02-28 | due-trials |
| Completed, but no date, and reported results | 2010-018976-25 | An open label non-controlled trial to evaluate the effect of dronedarone (Multaq® 400 mg BID) on the quality of life in patiënts with a history of, or current non-permanent atrial fibrillation (AF) | bad-data | |
| Reported results | 2010-018991-25 | Immunogenicity of the Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine Without Adjuvant in Healthy Adult Subjects | 2010-09-21 | due-trials |
| Reported results | 2010-019247-19 | A Randomized, international, multi-center, open-label study to document pharmacokinetics and optimal timing of initiation of dronedarone TreatmEnt following long-term aMIodarone in patients with parox... | 2012-04-18 | due-trials |
| Reported results | 2010-019255-22 | Ensayo aleatorizado de Fase III de gemcitabina/carboplatino con o sin BSI-201 (SAR240550) (un inhibidor de PARP1) en pacientes con cáncer de pulmón no microcítico (CPNM) epidermoide en estadío IV no t... | 2013-04-11 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2010-019262-86 | A multi-center, uncontrolled extension study evaluating efficacy and safety of SAR153191 on top of DMARDs in patients with active Rheumatoid Arthritis (RA Studio di estensione, multicentrico non co... | 2020-12-31 | bad-data |
| Reported results | 2010-019263-11 | A multicenter uncontrolled extension study evaluating the long term safety and efficacy of SAR153191 in patients with Ankylosing Spondylitis (AS) | 2011-12-12 | due-trials |
| Trial is partly outside EEC, and reported results | 2010-019340-40 | A Phase 1/2 Combined Dose Ranging and Randomised, Open-label, Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells... | 2017-05-09 | bad-data |
| Reported results | 2010-019384-11 | A multinational, randomized, double blind, controlled phase II trial of ombrabulin with taxane and platinum combination administered every three weeks, in first line treatment of patients with locally... | 2012-10-02 | due-trials |
| Reported results | 2010-019791-73 | A Randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of Dronedarone 400mg BID on top of standard therapy in patients with permanent atrial fibrillati... | 2011-11-21 | due-trials |
| Reported results | 2010-019835-37 | Safety and Immunogenicity of an Intramuscular H5N1 Inactivated, Split Virion Influenza Vaccine Adjuvanted with AF03 in Adults and Elderly subjects | 2010-12-07 | due-trials |
| Reported results | 2010-020611-36 | A Phase 4 Prospective Exploratory Muscle Biopsy, Biomarker, and Imaging Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa | 2013-12-19 | due-trials |
| Reported results | 2010-021020-94 | A randomized, double-blind, parallel-group, placebo- and active calibrator-controlled study assessing the clinical benefit of SAR153191 subcutaneous (SC) on top of methotrexate (MTX) in patients with ... | 2011-09-15 | due-trials |
| Reported results | 2010-021128-92 | Ensayo clínico multicéntrico, abierto y de un solo grupo para proporcionar acceso previo a la comercialización de cabazitaxel a los pacientes con cáncer de próstata metastásico hormono-resistente trat... | 2015-12-21 | due-trials |
| Reported results | 2010-021373-37 | Evaluation of Insuman Implantable 400 IU/ml in patients with Type 1 diabetes treated with the Medtronic MiniMed Implantable Pump System using Insuplant 400 IU/mL | 2018-02-01 | due-trials |
| Reported results | 2010-022064-12 | Estudio aleatorizado, abierto y multicéntrico de comparación de cabazitaxel a dosis de 25 mg/m2 y 20 mg/m2, administrado en combinación con prednisona cada 3 semanas, con docetaxel administrado en com... | 2018-05-23 | due-trials |
| Reported results | 2010-022163-35 | Estudio aleatorizado, abierto y multicéntrico de comparación de cabazitaxel a dosis de 20 mg/m2 y 25 mg/m2 administrado cada 3 semanas en combinación con prednisona para el tratamiento del cáncer de p... | 2015-08-19 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2010-022231-11 | A Phase 3/4 Prospective Study to Characterize the Pharmacokinetics of Alglucosidase Alfa in Patients Aged 8 Years of Age and Older | 2020-11-18 | bad-data |
| Reported results | 2010-022596-64 | A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance, safety, and tolerability of SAR110894D at the doses of 0.5 mg, ... | 2013-01-09 | due-trials |
| Trial is partly outside EEC, and reported results | 2010-023111-34 | A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected SAR422459, Administered to Patients with Stargardt's Macular Degeneration. | 2019-08-16 | bad-data |
| Reported results | 2010-023172-12 | A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta | 2013-04-24 | due-trials |
| Reported results | 2010-023400-28 | ENSAYO CLÍNICO RANDOMIZADO FASE II DE DOCETAXEL-CARBOPLATINO EN COMBINACIÓN CON INIPARIB (BSI-201), Y DOCETAXEL-CARBOPLATINO COMO TRATAMIENTO NEOADYUVANTE DE PACIENTES CON CÁNCER DE MAMA ESTADIO TEMP... | 2013-07-20 | due-trials |
| Listed as ongoing, but also has a completion date | 2010-023428-26 | A Randomized, International, Open-Label, Multi-Centre, Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients with Locally Advanced or Metastatic Medulla... | 2016-05-13 | bad-data |
| Reported results | 2010-023769-23 | 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both plus Mealtime Insulin in Patients with Ty... | 2013-09-04 | due-trials |
| Reported results | 2010-023770-39 | 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® both in combination with oral antihyperglycemi... | 2013-11-22 | due-trials |
| Listed as ongoing, but also has a completion date | 2010-023953-12 | A Phase 2, Multi-Center, Randomized, Open-Label, Repeat Dose, Dose-Comparison Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Human Acid Sphingomyelinase in Patients With A... | 2015-03-31 | bad-data |
| Reported results | 2010-024631-16 | A Phase 2, Multi-Center, Double-Blind, placebo controlled, Randomized Study of Ombrabulin in Patients with Platinum-Sensitive Recurrent Ovarian Cancer treated with Carboplatin/Paclitaxel | 2014-07-09 | due-trials |
| Reported results | 2011-001160-21 | Study to investigate the immune response to influenza vaccine in patients with multiple sclerosis on teriflunomide treatment and using a population of patients with multiple sclerosis as a reference | 2012-01-23 | due-trials |
| Reported results | 2011-001424-38 | A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 over 24 weeks in Patients with Hypercholesterolemia | 2013-07-09 | due-trials |
| Reported results | 2011-001480-42 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Continuation Period to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in... | 2016-03-15 | due-trials |
| Exempt, with results | 2011-001506-96 | A Phase I/II Study of Cabazitaxel Combined with Abiraterone Acetate and Prednisone in Patients with Metastatic Castrate-Resistant Prostate Cancer (CRPC) whose Disease has Progressed after Docetaxel C... | 2014-12-09 | not-yet-due |
| Reported results | 2011-001616-57 | A Phase 2 study of SAR245409 in patients with relapsed or refractory mantle cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma or diffuse large B-cell lymphoma | 2014-09-12 | due-trials |
| Reported results | 2011-001847-58 | A Randomized Phase II, Open-Label study of the Efficacy and Safety of Orally Administered SAR302503 in patients with polycythemia vera (PV) or essential thrombocythemia (ET) who are resistant or intol... | 2014-05-19 | due-trials |
| Reported results | 2011-001876-21 | MULTINATIONAL, MULTICENTER, RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF EFFICACY AND SAFETY OF SAR292833 ADMINISTRATION FOR 4 WEEKS IN PATIENTS WITH CHRONIC PERIPHERAL NEUROPA... | 2013-05-09 | due-trials |
| Reported results | 2011-001897-25 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis,... | 2014-07-04 | due-trials |
| Reported results | 2011-001976-21 | Safety and Immunogenicity of a Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Adult and Elderly Subjects | 2012-06-11 | due-trials |
| Reported results | 2011-002090-36 | A randomized, 24-week, open-label, 2-arm parallel-group, multicenter study comparing the efficacy and safety of insulin glargine/lixisenatide fixed ratio combination versus insulin glargine on top of ... | 2012-12-17 | due-trials |
| Reported results | 2011-002329-23 | A 2-Week, Randomized, Placebo-Controlled, Fixed Dose Period Followed by a 6-Month, Single-Arm, Open-Label, Dose Titration Period Study to Investigate the Efficacy and Safety of Sevelamer Carbonate in ... | 2015-06-16 | due-trials |
| Reported results | 2011-002416-85 | A 24-week, open-label, randomized, 2-arm parallel group, multinational, multi-center clinical trial to compare the efficacy and safety of lixisenatide injected prior to the main meal of the day versus... | 2013-05-17 | due-trials |
| Reported results Terminated | 2011-002557-56 | A randomized, double-blind, parallel-group, placebo-controlled study to assess the clinical benefit of SSR411298 as adjunctive treatment for persistent cancer pain | 2012-03-27 | due-trials |
| Reported results | 2011-002806-59 | Long-term Safety and Tolerability of REGN727/SAR236553 in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy: A Randomized, Double... | 2015-01-16 | due-trials |
| Completed, but no date, and reported results | 2011-002865-39 | An open label, multicenter phase II study of intravenous SAR3419, an anti-CD19 antibody-maytansine conjugate, in combination with rituximab in patients with relapsed or refractory Diffuse Large B Cell... | bad-data | |
| Exempt, with results | 2011-003232-31 | A two part protocol to assess, using double blind placebo control, the safety, tolerability, and pharmacokinetics of ascending single doses of a new intra-articular administration formulation of SAR11... | 2013-05-02 | not-yet-due |
| Reported results | 2011-003415-31 | Randomized Phase II Study of Cabazitaxel versus Topotecan in Small Cell Lung Cancer Patients with Progressive Disease during or after a First Line Platinum Based Chemotherapy | 2014-04-02 | due-trials |
| Reported results | 2011-003538-16 | A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing The Efficacy and Safety of Sarilumab Added To DMARD Therapy In Patients With Rheumatoid Arthritis Who Are Inadequate Responders... | 2015-03-23 | due-trials |
| Listed as ongoing, but also has a completion date | 2011-003576-36 | A Phase II Randomized Open Label Study of MM-121 in combination with Paclitaxel versus Paclitaxel alone in patient with Platinum Resistant/Refractory Advanced Ovarian Cancers. | 2015-02-13 | bad-data |
| Reported results | 2011-003657-26 | An open label non-randomized phase 2 study evaluating SAR3419, an anti-CD19 antibody ? maytansine conjugate, administered as single agent by intravenous infusion to patients with relapsed or refractor... | 2016-10-04 | due-trials |
| Trial is outside EEC, and reported results | 2011-004095-10 | A Phase III Randomized, Open-Label, Active-Comparator Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Infants When Given at 2, 4, and 6 Months Concomitant... | bad-data | |
| Trial is outside EEC, and reported results | 2011-004108-39 | A Phase III Randomized, Partially Double-Blind, Active- Comparator-Controlled, Lot-to-Lot Consistency Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants... | bad-data | |
| Reported results | 2011-004130-34 | A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 Versus Ezetimibe in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately... | 2015-07-28 | due-trials |
| Trial is outside EEC, and reported results | 2011-004428-36 | Phase III, A3L24 extension protocol, randomized, blind-observer, multi-center booster vaccination study in toddlers who completed a three-dose primary series of DTaP-IPV-Hep B-PRP-T combined vaccine o... | bad-data | |
| Trial is outside EEC, and reported results | 2011-004431-31 | Phase III, randomized, blind-observer, multi-center, four-arm, parallel-group trial in 2133 infants | bad-data | |
| Trial is outside EEC, and reported results | 2011-004432-58 | Phase III, open-label, and mono-center booster vaccination study in toddlers who completed a three-dose primary series of DTaP-IPV-Hep B-PRP-T combined vaccine or of Pentaxim™ and Engerix™ B in Study ... | bad-data | |
| Trial is outside EEC, and reported results | 2011-004433-14 | Randomized, open, controlled, multicenter, Phase III trial in infants who will receive DTaP-IPV-Hep B-PRP-T (Group 1, N=286), CombAct-Hib™ and Engerix B™ Pediatric with OPV (Group 2, N=286), or DTaP-I... | bad-data | |
| Trial is outside EEC, and reported results | 2011-004434-33 | Phase III, randomized, blind-observer, single-center, controlled trial of the DTaP-IPV-Hep B-PRP-T vaccine in 266 healthy Peruvian infants. | bad-data | |
| Trial is outside EEC, and reported results | 2011-004449-42 | Multi-center, randomized, observer blinded, Phase III trial in 1,376 infants, using Infanrix hexa™ as the control vaccine. Four-arm trial with subjects randomly allocated to receive 1 of 3 lots of DTa... | bad-data | |
| Trial is outside EEC, and reported results | 2011-004450-26 | Phase III, multi-center study in children fully vaccinated with a three-dose primary and the booster dose of the DTaP-IPV-Hep B-PRP-T combined vaccine or CombAct-Hib™ and OPV and Engerix™ B in Study A... | bad-data | |
| Trial is outside EEC, and reported results | 2011-004451-39 | Evaluation of Antibody Persistence at 3.5 and 4.5 Years of Age in Healthy Children After Primary Series and Booster Vaccination with Investigational (DTaP-IPV-HB-Hib) or Infanrix™ hexa vaccines in Lat... | bad-data | |
| Trial is outside EEC, and reported results | 2011-004454-26 | Mono-center, open-label, randomized, active-controlled trial in 310 infants | bad-data | |
| Trial is outside EEC, and reported results | 2011-004455-39 | Phase III, randomized, blind-observer, multicenter, four-arm study of three batches of the DTaP-IPV-Hep B-PRP-T vaccine and one arm receiving Infanrix hexa™. | bad-data | |
| Trial is outside EEC, and reported results | 2011-004456-19 | Phase III, open-label, multi-center booster vaccination study in toddlers who completed a three-dose primary series of the DTaP-IPV-Hep B-PRP-T combined vaccine or Infanrix hexa™ in Study A3L11. | bad-data | |
| Trial is outside EEC, and reported results | 2011-004457-87 | A Phase III, randomized, blind-observer, controlled, multicenter trial in 412 infants in Thailand. | bad-data | |
| Trial is partly outside EEC, and reported results | 2011-004584-67 | A randomized, double-blind, placebo controlled trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of lixisenatide in paediatric (10 - 17 years old) and adult patients with typ... | 2014-03-04 | bad-data |
| Listed as ongoing, but also has a completion date | 2011-004701-24 | An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thy... | 2016-06-29 | bad-data |
| Reported results | 2011-004783-30 | A pilot, exploratory, randomized, phase 2 safety study evaluating tumor cell (plasma cell) mobilization and apheresis product contamination in plerixafor plus non-pegylated G-CSF mobilized patients an... | 2016-09-28 | due-trials |
| Trial is outside EEC, and reported results | 2011-005101-79 | Safety and Immunogenicity of a Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Child/Adolescent and Adult Subjects | bad-data | |
| Reported results | 2011-005109-56 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately... | 2014-12-05 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-005155-14 | An open-label, pharmacokinetic, pharmacodynamic, and tolerability study of AVE5026 administered at weight-adjusted doses to patients under 18 years of age with a Central Venous Line (CVL) | 2012-06-26 | bad-data |
| Reported results | 2011-005226-21 | A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated with Ruxolitinib and with a Current Diagnosis of Intermediate-2 or High-Risk Primary Myelofibrosis, P... | 2014-04-29 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-005249-12 | A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once D... | bad-data | |
| Reported results | 2011-005374-33 | Safety and Immunogenicity of the Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Children Aged 3 to 8 Years | 2014-06-26 | due-trials |
| Reported results | 2011-005595-42 | A Phase 3/4, Prospective, Multinational, Open-label, Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients with Infantile-Onset Pompe Disea... | 2014-12-01 | due-trials |
| Reported results | 2011-005698-21 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently E... | 2018-01-23 | due-trials |
| Reported results | 2011-005724-17 | A Multicenter, Single arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients with Metastatic Colorectal Cancer (mCRC) Previously Treated wi... | 2017-01-31 | due-trials |
| Reported results | 2011-006140-78 | International, multicenter, open-label, treatment-extension study for subjects who completed a Phase 1 or Phase 2 parental study to continue receiving treatment with SAR245408 or SAR245409 as a monoth... | 2018-05-23 | due-trials |
| Reported results | 2011-006246-33 | International, Multi-Center, Open-label, Treatment Extension Study of Iniparib as Monotherapy or in Combination Chemotherapeutic Regimens in Cancer Patients Who Have Derived Clinical Benefit From Inip... | 2016-09-26 | due-trials |
| Reported results | 2012-000027-40 | An open-label, randomized, three-parallel-group study on pharmacodynamic effects of 8-week QD treatment with lixisenatide compared to liraglutide in patients with type 2 diabetes not adequately contro... | 2013-07-25 | due-trials |
| Reported results | 2012-000048-89 | A Multicenter, Single arm, Open Label Clinical Trial Evaluating Safety and Health-Related Quality of Life of Aflibercept in Combination with Irinotecan/5FU chemotherapy (FOLFIRI) in Patients with Met... | 2015-06-09 | due-trials |
| Reported results | 2012-000146-35 | 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Insulin-Naïve Patients with Type 2 Diabetes... | 2014-03-26 | due-trials |
| Reported results | 2012-001042-18 | Booster Effect and Safety of a DTaP-IPV-Hib Combined Vaccine, with or without Hep B, in Healthy Subjects 11 to 18 Months of Age Who Received a Hexavalent or Hexavalent/Pentavalent Combined Vaccine dur... | 2015-10-27 | due-trials |
| Reported results | 2012-001054-26 | Immunogenicity and Safety Study of a Hexavalent DTaP-IPV-Hep B-PRP-T Combined Vaccine or Infanrix hexa™ Concomitantly Administered With 13-Valent Pneumococcal Conjugate Vaccine (PCV13), at 3, 5, 11 to... | 2014-01-10 | due-trials |
| Reported results | 2012-001055-39 | Phase III, multi-center trial in 795 infants in the Czech Republic, Germany, and Spain. Subjects from the Czech Republic and Germany will be randomized in Groups 1 and 2 to receive in a blind-observer... | 2014-11-27 | due-trials |
| Completed, but no date, and reported results | 2012-001096-37 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to evaluate the Efficacy and Safety of SAR236553 (REGN727) in Patients With Heterozygous Familial Hypercholesterolemia and LDL-C hi... | bad-data | |
| Reported results | 2012-001369-34 | Double-blind, randomized, 8-week placebo-controlled and 16-week open label extension study investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients with Di... | 2014-04-02 | due-trials |
| Reported results | 2012-001524-35 | A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected in the Morning or Evening in Patien... | 2014-03-14 | due-trials |
| Exempt, with results | 2012-001966-14 | A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients with Fabry Disease Estudio transversal sobre la función renal en varones jóvenes con enfermedad de Fabry sin tratam... | 2016-08-17 | not-yet-due |
| Reported results | 2012-001984-66 | A Randomized, Controlled Study of Sarilumab and Methotrexate (MTX) Versus Etanercept and MTX in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to 4 Months of Treatment with Adalimu... | 2015-01-12 | due-trials |
| Reported results | 2012-002013-19 | A randomized, double-blind, placebo-controlled, multicenter study evaluating efficacy and safety of SAR339658 in patients with active moderate to severe Ulcerative Colitis (UC). | 2014-05-20 | due-trials |
| Reported results | 2012-002365-35 | A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis | 2015-01-27 | due-trials |
| Exempt, with results | 2012-002574-31 | A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected SAR421869, Administered to Patients with Retinitis Pigmentosa Associated with Usher Syndrome Type 1B | 2019-08-16 | not-yet-due |
| Reported results | 2012-002961-36 | Phase II two stage dose finding run-in study of SAR3419, an anti-CD19 antibody-maytansine conjugate,administered as a single agent by intravenous infusion in patients with relapsed or Refractory Acute... | 2014-05-23 | due-trials |
| Reported results | 2012-003292-19 | A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter, 24 week study assessing the safety and efficacy of lixisenatide in older patients with type 2 diabetes inadequately c... | 2015-02-19 | due-trials |
| Reported results | 2012-003536-23 | A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant o... | 2014-10-14 | due-trials |
| Reported results | 2012-004096-38 | A randomized, open-label, active-controlled, 3-arm parallel-group, 26- week study comparing the efficacy and safety of lixisenatide to that of insulin glulisine once daily and insulin glulisine thre... | 2015-12-23 | due-trials |
| Reported results | 2012-004339-21 | A Multicenter, Randomized, Open-Label, Parallel-Group Usability Study Of The Sarilumab Auto-Injector Device And A Prefilled Syringe In Patients With Moderate To Severe Active Rheumatoid Arthritis Who ... | 2016-03-11 | due-trials |
| Reported results | 2012-004845-34 | A Randomized, Double-Masked and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sarilumab Administered Subcutaneously Every 2 Weeks in Patients with Non-Infectious, Intermediate, Poste... | 2016-04-19 | due-trials |
| Completed, but no date, and reported results | 2012-005243-25 | Immunogenicity and Safety of the Trivalent Influenza Vaccine (Split-Virion, Inactivated), Northern Hemisphere 2013-2014 Formulation (Intradermal Route) | bad-data | |
| Reported results | 2012-005324-16 | Exploratory Open Label Study to Investigate the Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Relapsing Forms of Multiple Sclerosis | 2015-01-22 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-000051-40 | A Long-Term Study to Assess the Ongoing Safety and Efficacy of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency | 2023-09-06 | bad-data |
| Completed, but no date, and reported results Terminated | 2013-000420-34 | Etude de phase IV, de non infériorité, multicentrique, randomisée, en double aveugle, comparant la pristinamycine (2g x 2 par jour pendant 2 jours puis 1g x 3 par jour pendant 5 à 7 jours) à l’amoxici... | bad-data | |
| Listed as ongoing, but also has a completion date | 2013-000422-58 | A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA?) 300 mg in Patients with Papillary or Poorly Differentiated Thyr... | 2022-01-10 | bad-data |
| Reported results | 2013-000775-32 | Efficacy, Immunogenicity, and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C. difficile Infection | 2018-06-12 | due-trials |
| Reported results | 2013-000856-16 | A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients with Moderate to Severe Uncontrolled Asthma | 2015-04-08 | due-trials |
| Exempt, with results | 2013-000858-22 | A Single-Arm, Open Label Study of Aflibercept as Maintenance Therapy Following Induction with Aflibercept in Combination with XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient ... | not-yet-due | |
| Reported results | 2013-001012-30 | A Multicenter Single-Arm Open Label Extension Study Evaluating The Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC) | 2014-05-08 | due-trials |
| Reported results | 2013-001231-51 | Efficacy and Immunogenicity Study of Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Healthy Children Aged 6 to 35 Months | 2016-07-27 | due-trials |
| Listed as ongoing, but also has a completion date | 2013-001418-13 | A Phase 1/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD3... | 2023-07-13 | bad-data |
| Reported results | 2013-001439-34 | A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (... | 2015-11-19 | due-trials |
| Reported results | 2013-001803-35 | A Randomized, Double-Blind, Phase 2, Placebo Controlled, 2 Arm Study To Evaluate Dupilumab In Patients With Bilateral Nasal Polyposis And Chronic Symptoms Of Sinusitis | 2014-12-05 | due-trials |
| Reported results | 2013-002572-40 | Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemi... | 2017-06-30 | due-trials |
| Reported results | 2013-002659-14 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Alirocumab in Patients with Primary Hypercholesterolemia Not Treated With a Statin | 2017-06-30 | due-trials |
| Reported results | 2013-002790-22 | An open-label, randomized, parallel group study assessing the immunogenicity and safety of sarilumab administered as monotherapy in patients with active rheumatoid arthritis | 2015-05-26 | due-trials |
| Reported results | 2013-002945-12 | Six-month, Randomized, Open-label, Parallel-group Comparison of SAR342434 to Humalog® in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine, with a 6-month Safety Extension Perio... | 2016-07-01 | due-trials |
| Reported results | 2013-003131-30 | A randomized, 30 week, active-controlled, open-label, 3-treatment arm, parallel-group multicenter study comparing the efficacy and safety of insulin glargine/ lixisenatide fixed ratio combination to i... | 2015-06-17 | due-trials |
| Reported results | 2013-003132-79 | A randomized, 30-week, active-controlled, open label, 2-treatment arm, parallel-group, multicenter study comparing the efficacy and safety of the insulin glargine/lixisenatide fixed ratio combination ... | 2015-07-09 | due-trials |
| Reported results | 2013-003267-55 | An international, multicenter, open-label, one-arm study in 150 infants vaccinated with a 3-dose primary series of the DTaP-IPV-Hep B-PRP-T combined vaccine in the Russian Federation and Poland. | 2016-08-29 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-003321-28 | An Open-Label, Multicenter, Multinational Extension Study Of The Long-Term Safety And Pharmacokinetics Of Repeated Biweekly Infusions Of Avalglucosidase Alfa (NeoGAA, GZ402666) In Patients With Pompe ... | 2022-12-12 | bad-data |
| Trial is partly outside EEC, and reported results | 2013-003856-19 | Open label extension study to evaluate the long-term safety and tolerability of dupilumab in patients with asthma who participated in previous dupilumab asthma clinical study Estudio de extensión a... | 2019-10-11 | bad-data |
| Reported results | 2013-003884-71 | A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409) | 2020-07-15 | due-trials |
| Reported results | 2013-005324-41 | A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Enzyme Replacement Therapy (ERT) Treatment-naïve Adult Male Patients Diagnosed w... | 2016-09-06 | due-trials |
| Reported results | 2014-000092-62 | Single arm study to assess comprehensive infusion guidance for the management of the infusion associated reaction (IARs) in Relapsing-Remitting Multiple Sclerosis (RRMS) patients treated with Lemtrada... | 2016-04-01 | due-trials |
| Completed, but no date | 2014-000629-19 | Safety assessment of the Trivalent Influenza Vaccine (Split-Virion, Inactivated), Northern Hemisphere 2014-2015 Formulation (Intradermal Route) | bad-data | |
| Reported results | 2014-000785-21 | Immunogenicity and Lot-to-Lot Consistency Study of a Quadrivalent Influenza Vaccine in Adult and Elderly Subjects | 2015-10-23 | due-trials |
| Reported results | 2014-001253-16 | A multi-center, open-label, single-arm, multiple dose study with HOE901-U300 to assess the Ease of Use and Safety of a new U300 pen injector in insulin-naïve patients with T2DM Eine multizentrische... | 2014-11-20 | due-trials |
| Trial is outside EEC, and reported results | 2014-001534-29 | Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Subjects Aged 2 to 45 Years in the Philippines | bad-data | |
| Reported results | 2014-001643-20 | A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) | 2016-07-07 | due-trials |
| Trial is outside EEC, and reported results | 2014-001694-14 | A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines | bad-data | |
| Trial is outside EEC, and reported results | 2014-001706-17 | Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Subjects Aged 2 to 45 Years in Mexico | bad-data | |
| Trial is outside EEC, and reported results | 2014-001707-53 | Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America | bad-data | |
| Trial is outside EEC, and reported results | 2014-001708-24 | Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia | bad-data | |
| Trial is outside EEC, and reported results | 2014-001709-41 | Immunogenicity and Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam | bad-data | |
| Trial is outside EEC, and reported results | 2014-001710-25 | Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 11 Years in Thailand | bad-data | |
| Trial is outside EEC, and reported results | 2014-001711-40 | Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years | bad-data | |
| Trial is outside EEC, and reported results | 2014-001713-26 | Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore | bad-data | |
| Trial is outside EEC, and reported results | 2014-001714-26 | Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly with Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru | bad-data | |
| Trial is outside EEC, and reported results | 2014-001715-39 | Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America | bad-data | |
| Trial is outside EEC, and reported results | 2014-001716-19 | Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America | bad-data | |
| Trial is outside EEC, and reported results | 2014-001717-11 | Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia | bad-data | |
| Trial is outside EEC, and reported results | 2014-001736-11 | Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly with Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico | bad-data | |
| Trial is outside EEC, and reported results | 2014-001737-88 | Long-Term Safety Follow-Up of Thai Children Who Were Included in an Efficacy Study of a Tetravalent Dengue Vaccine | bad-data | |
| Completed, but no date, and reported results Terminated | 2014-002263-15 | Effects of GLP-1 Receptor Agonist Lixisenatide on Post-prandial Lipid Profile in Obese Type 2 Diabetic Patients Effetti della Lixisenatide, agonista del recettore GLP-1, sul profilo lipidico post-p... | bad-data | |
| Reported results | 2014-002399-10 | A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients with Type 2 Diabetes Inadequately Controlled... | 2016-05-20 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-002541-22 | A randomized, double-blind, parallel-group study assessing the efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis | 2020-12-29 | bad-data |
| Ongoing | 2014-002550-39 | 4-part, open-label, multicenter, multinational study of the safety, tolerability, pharmacokinetics, pharmacodynamic, and exploratory efficacy of venglustat in combination with Cerezyme in adult patien... | not-yet-due | |
| Reported results | 2014-002844-42 | Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog® in Adult Patients With Type 2 Diabetes Mellitus also Using Insulin Glargine | 2016-02-16 | due-trials |
| Trial is outside EEC, and reported results | 2014-002867-13 | Multinational, randomized, double blind, double dummy, pharmacokinetic study of telithromycin oral suspension (25 mg/kg once daily for 7-10 days), with secondary assessments of safety relative to azit... | bad-data | |
| Trial is partly outside EEC, and reported results | 2014-003198-40 | A Phase 1/2, Multi-Center, Open-Label, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Exploratory Efficacy of Recombinant Human Acid Sphingomyelinase... | 2019-12-09 | bad-data |
| Reported results Terminated | 2014-003265-19 | A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839 | 2016-07-07 | due-trials |
| Reported results | 2014-003933-24 | Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (IPF): A Randomized, Double-blind, Placebo-controlled, 52-week Dose-ranging Study | 2017-08-14 | due-trials |
| Trial is outside EEC, and reported results | 2014-003989-24 | Program of Rasburicase in the Treatment of Hyperuricemia in Children and Adolescent Patients With or at Risk of Tumor Lysis Syndrome | bad-data | |
| Trial is outside EEC, and reported results | 2014-004002-15 | Local, Phase IV, Multicenter, Double-blind, Randomized, Parallel, With Two Treatment Arms, Placebo-controlled Study to Evaluate the Reduction of Inflammatory Symptoms in the Treatment of Bacterial Pha... | bad-data | |
| Completed, but no date, and reported results | 2014-004367-20 | A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccines in Healthy Toddlers | bad-data | |
| Reported results | 2014-004533-13 | A 21-Week, Open-label, Randomized, Controlled, Parallel-group, Multi-center Study Evaluating the Efficacy and Safety of HOE901-U300 Administered According to a Device-Supported Treat-to-target Regimen... | 2016-11-29 | due-trials |
| Trial is outside EEC, and reported results | 2014-004628-23 | Comparison of Teicoplanin and Vancomycin in Terms of Efficacy and Side Effect Profile During Initial Antibiotic Treatment of Febrile Neutropenic Patients at High Risk For Gram-Positive Infection: Mult... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004629-42 | Bacillus Clausii in Preventing Antibiotic-Associated Diarrhea Among Filipino Infant and Children: A Multi-Center, Randomized, Open-Label Controlled (Treatment vs No Treatment) Clinical Trial of Effica... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004630-26 | Multinational, Randomized, Double-Blind, Double Dummy, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 25mg/kg od Versus 10 Days Penicillin V 13.3 mg/kg Tid in Children 6... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004631-39 | Multinational, randomized, double blind, comparative study to evaluate the efficacy and safety of telithromycin, 800 mg once daily for 5 days, versus penicillin V, 500 mg three times daily for 10 days... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004636-19 | Phase III Comparative Study to Assess the Efficacy and Safety of Oral Rehydration Therapy (ORT) in Combination With Spores of Bacillus Clausii (Enterogermina)Versus ORT Alone, Administered for 5 Days ... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004637-47 | Multinational, Randomized, Double-Blind, Double-Dummy, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 25mg/kg od Versus 5 Days Azithromycin 10 mg/kg od Followed by 5 mg/... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004639-38 | A study of effectiveness and safety of Apidra in combination with Lantus therapy in basal-bolus insulin regimen in inadequately controlled children and adolescents with Type 1 diabetes in the Russian ... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004640-35 | A 24-week, Randomized, Open-label, Parallel Group, Multicenter Comparison of Lantus® (Insulin Glargine) Given Once Daily Versus Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabete... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004643-12 | Post-marketing study of Amaryl® (Glimepiride) in patients with type 2 diabetes to investigate pediatric and adult population pharmacokinetics [multicenter, non-comparative, 12-28 weeks, non-blind titr... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004644-35 | Single dose, open label safety, tolerability, pharmacokinetic and pharmacodynamic evaluation of three different eplivanserin doses in children aged 6-17 years with insomnia of various origins | bad-data | |
| Trial is outside EEC, and reported results | 2014-004645-27 | A randomized, multicenter, double-blind, placebo-controlled, parallel group study of the 12 month effect of treatment with once daily triamcinolone acetonide (NASACORT® AQ Nasal Spray 110 μg) on the g... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004646-98 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Pharmacodynamic Effect of a 6-week Treatment With Triamcinolone Acetonide Aqueous Nasal Spray 110 μg an... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004659-30 | Four-week, open-label, multicenter, randomized, parallel-group study to investigate the pharmacokinetics, safety, tolerability and the effects on leak point pressure of 2 oral doses of alfuzosin (0.1 ... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004660-37 | Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet Flower | bad-data | |
| Trial is outside EEC, and reported results | 2014-004661-25 | Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Tangerina Mix | bad-data | |
| Trial is outside EEC, and reported results | 2014-004662-26 | Safety Dermatological Evaluation: genital Mucosa Irritation - Product tested: Dermacyd PH_DETINLYN Sweet Flower. | bad-data | |
| Trial is outside EEC, and reported results | 2014-004663-20 | Safety Dermatological Evaluation: genital mucosa irritation - Product tested: Dermacyd PH_DETINBACK Sweet Flower | bad-data | |
| Trial is outside EEC, and reported results | 2014-004664-38 | Safety Dermatological Evaluation: genital mucosa irritation - Product tested: Dermacyd PH_DETINLYN Tangerine Mix. | bad-data | |
| Trial is outside EEC, and reported results | 2014-004665-24 | Safety Dermatological Evaluation: genital mucosa irritation - Product tested: Dermacyd PH_DETINBACK Tangerine Mix. | bad-data | |
| Trial is outside EEC, and reported results | 2014-004666-14 | Safety Dermatological Evaluation: acceptability with pediatric follow up – Dermacyd Infantile LACAC_L_04678 | bad-data | |
| Reported results | 2014-004676-29 | A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR)- targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated with Docetaxel and Who Ra... | 2021-03-15 | due-trials |
| Exempt, with results | 2014-004805-34 | A Two Part Protocol Using Double Blind Placebo Control to Assess the Safety, Tolerability, and Pharmacokinetics of Single Escalating Intra-articular Doses Followed by Assessment of Efficacy, Safety, T... | not-yet-due | |
| Reported results | 2014-004850-32 | A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults with Type 2 Diabetes... | 2018-11-17 | due-trials |
| Trial is partly outside EEC, and reported results | 2014-004940-36 | A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Persistent Asthma | 2017-11-23 | bad-data |
| Reported results | 2014-004995-49 | An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Adult Male Patients Diagnosed with Fabry Disease | 2018-11-20 | due-trials |
| Exempt, with results | 2014-005047-40 | A Randomized, Double Blind, Single Dose, Crossover Study, in Subjects with Mild to Moderate Asthma, to Compare the Pharmacodynamic (Bronchodilator) Responses of 12.5/250 µg and 50/250 µg Salmeterol / ... | 2015-08-25 | not-yet-due |
| Reported results | 2014-005696-93 | Phase II, Open Label, Single Arm Study Assessing the Clinical Benefit of SAR125844, Administered as Single Agent by Weekly Intravenous (IV) Infusion, for the Treatment of Patients with Advanced Pretre... | 2016-01-05 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-000371-26 | A Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Repeat Dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of olipudase alfa in Patients With Ac... | 2023-10-19 | bad-data |
| Completed, but no date | 2015-000479-28 | A Phase II Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia Otevřená studie fáze II hodnotící sargramostim u pacientů... | bad-data | |
| Trial is outside EEC, and reported results | 2015-000512-18 | A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale | bad-data | |
| Trial is outside EEC, and reported results | 2015-000582-31 | An Exploratory, Open-Label Study of the Safety and Efficacy of High Dose or High Dosing Frequency Myozyme® (alglucosidase alfa) Treatment in Patients with Pompe Disease Who Do Not Have an Optimal Resp... | bad-data | |
| Trial is outside EEC, and reported results | 2015-000583-34 | An Exploratory Study of the Safety and Efficacy of Immune Tolerance Induction (ITI) in Patients with Pompe Disease Who Have Previously Received Myozyme | bad-data | |
| Trial is outside EEC, and reported results | 2015-000584-14 | An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naïve CRIM(-) Patients with Infantile-Onset Pompe Disease | bad-data | |
| Trial is outside EEC, and reported results | 2015-000585-61 | A Multicenter, Multinational, Open-Label Study of Anti-Laronidase Antibody Formation and Urinary GAG Levels in Patients with Mucopolysaccaridosis I (MPS I) Being Treated with Aldurazyme® (laronidase) | bad-data | |
| Reported results | 2015-000620-28 | A Multi-Country, Multicenter, Single-Arm, Open-Label Study to Document the Safety, Tolerability and Effect of Alirocumab on atherogenic lipoproteins in High Cardio-Vascular Risk Patients With Severe H... | 2019-04-12 | due-trials |
| Trial is outside EEC, and reported results | 2015-000697-35 | Evaluation of Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta (The INFORM Study) | bad-data | |
| Reported results | 2015-000799-92 | A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of Alirocumab in insulin treated patients with type 1 or type 2 diabetes and with hypercholeste... | 2017-04-03 | due-trials |
| Completed, but no date, and reported results | 2015-001167-39 | Studio nazionale, randomizzato, controllato, in aperto, a gruppi paralleli per confrontare l’efficacia e la sicurezza di due diversi approcci con algoritmo di titolazione (gestito dal medico vs gestit... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001172-21 | A Phase 1, Open-label, Multi-center Study of Clofarabine in Japanese Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia | bad-data | |
| Trial is outside EEC, and reported results | 2015-001173-41 | An Open-Label, Multi-Center Safety and Tolerability Pilot Combination Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Patients with Acute Lymphoblasti... | bad-data | |
| Trial is outside EEC, and reported results | 2015-001174-18 | A Phase I/II Dose-Escalation Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute Leukemias | bad-data | |
| Reported results | 2015-001186-46 | A 28-week, prospective, single-arm, open label phase 4 study to evaluate treatment optimization with once-daily insulin glargine HOE901-300 IU/ml in combination with prandial rapid-acting insulin anal... | 2018-05-10 | due-trials |
| Trial is outside EEC, and reported results | 2015-001245-89 | Relative bioavailability study between 75 mg tablet and 75 mg solution of Clopidogrel (SR25990C) after single oral administration to young healthy men. Open, crossover, randomized and monocenter study | bad-data | |
| Reported results | 2015-001314-10 | A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids | 2018-11-16 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-001395-21 | An Open-Label Extension Study of Subcutaneously Administered Fitusiran in Patients with Moderate or Severe Hemophilia A or B who Have Participated In A Previous Clinical Study with Fitusiran | 2023-03-20 | bad-data |
| Reported results | 2015-001572-22 | An exploratory, randomized, double-blind, placebo-controlled study of the effects of dupilumab on airway inflammation of adults with persistent asthma | 2018-01-03 | due-trials |
| Reported results | 2015-001573-40 | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Severe Steroid Dependent Asthma | 2017-11-13 | due-trials |
| Reported results | 2015-001626-42 | A 24-Week, Multicenter, Randomized, Open-Label, 2-Arm Parallel-group Study Evaluating the Efficacy and Safety of Patient- Versus Physician-managed Titration of Insulin Glargine U300 in Type 2 Diabetes... | 2017-06-02 | due-trials |
| Reported results | 2015-001831-18 | A twenty six week, randomized, open-label, 2-arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of Toujeo® compared to standard of care insulin for initia... | 2017-10-16 | due-trials |
| Reported results | 2015-001832-39 | A twenty-six week, randomized, open-label, 2-arm parallel group real world pragmatic trial to assess the clinical and health outcomes benefit of transition to Toujeo compared to standard of care insul... | 2017-10-20 | due-trials |
| Reported results | 2015-001934-19 | A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients with Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk w... | 2017-05-18 | due-trials |
| Trial is partly outside EEC, and reported results | 2015-002084-42 | 6-Month, Multicenter, Randomized, Open-label, 2-Arm, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected Once Daily in Children and Ado... | 2018-12-20 | bad-data |
| Trial is outside EEC, and reported results | 2015-002184-42 | A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients with Refractory Solid Tumors Including Tumors of the Central Nervous System | bad-data | |
| Reported results | 2015-002416-33 | An interventional, Open-label, single-arm, multicenter, 24 Weeks phase 4 study assessing the Efficacy and Safety of Toujeo in patients with Type 2 Diabetes inadequately controlled with Basal Insulin... | 2017-07-24 | due-trials |
| Reported results | 2015-003101-42 | A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab 300 mg Every Other Week, in Patients with Bilateral Nasal Polyposis on a Background Therapy wit... | 2018-07-05 | due-trials |
| Trial is outside EEC, and reported results | 2015-003190-14 | Safety of Two Doses of Avaxim® 80U Pediatric (Inactivated Hepatitis A vaccine) Administered 6 Months Apart in Healthy Toddlers, Children and Adolescents Aged 12 Months to 15 Years in China | bad-data | |
| Trial is outside EEC, and reported results | 2015-003203-30 | Immunogenicity and Safety of the Purified Vero Rabies Vaccine- Serum Free (VRVg) in Comparison with the Human Diploid Cell Vaccine, IMOVAX® Rabies in a Pre-exposure Prophylaxis Regimen in Healthy Chil... | bad-data | |
| Trial is outside EEC, and reported results | 2015-003279-31 | Immunogenicity and Safety of IMOVAX POLIO® Subcutaneous as a Booster Given in Pre-school Age Children in Japan (IPV46) | bad-data | |
| Trial is outside EEC, and reported results | 2015-003500-23 | Safety and Immunogenicity of Tdap Vaccine Compared to DTaP vaccine as Fifth Dose Booster in Children 4 to 6 Years of Age | bad-data | |
| Reported results | 2015-003564-37 | An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment with the BTK Inhibitor PRN1008 in Patients with Newly Diagnose... | 2020-01-10 | due-trials |
| Completed, but no date, and reported results | 2015-003749-24 | Effects of MagneB6® (470.0 mg Magnesium Lactate Dihydrate + 5.0 mg Pyridoxine Hydrochloride, Coated Tablet) Supplementation (8 Weeks) on Stress Levels of Chronically Stressed Subjects, with Suboptimal... | bad-data | |
| Trial is partly outside EEC, and reported results | 2015-003766-85 | An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents with Heterozygous Familial Hypercholesterolemia Followed by ... | 2019-02-22 | bad-data |
| Trial is outside EEC, and reported results | 2015-003914-25 | Clinical Safety Study of the Tdap Combined Vaccine (ADACEL) as a Booster Dose in Healthy Adults and Children in China | bad-data | |
| Trial is outside EEC, and reported results | 2015-003941-24 | Immunogenicity and Safety of Sanofi Pasteur’s Tdap Combined Vaccine (ADACEL) as a Booster Dose, versus Local DT Vaccine in Healthy Children or versus Local Td Vaccine in Healthy Adolescents and Adults... | bad-data | |
| Trial is outside EEC, and reported results | 2015-003950-41 | Immunogenicity and safety of the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (SP306) given intramuscularly compared to Diphtheria and Tetanus toxoids adsorbed (D... | bad-data | |
| Trial is partly outside EEC | 2015-003999-79 | An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, with Polyarticular-cours... | 2023-12-27 | bad-data |
| Trial is partly outside EEC | 2015-004000-35 | An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, with Systemic Juvenile I... | bad-data | |
| Reported results | 2015-004715-20 | Phase IV study to evaluate the safety and efficacy of the treatment of hyperglycemia with Gla-300 in basal-bolus regimen in hospitalised T2D patients poorly controlled with basal insulin and/or non-in... | 2018-07-17 | due-trials |
| Reported results | 2015-004843-38 | A Randomized, Double-blind, 2x2 Cross-over Euglycemic Clamp Study in Two Parallel Cohorts to Compare the Pharmacodynamic and Pharmacokinetic Properties of 0.4 and 0.6 U/kg/day Insulin Glargine (Toujeo... | 2016-07-09 | due-trials |
| Reported results | 2015-005101-36 | A 24-Week, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of Toujeo® and Tresiba® in Insulin-Naive Patients with Type 2 Diabetes Mellitus Not Adequately Co... | 2017-08-15 | due-trials |
| Trial is outside EEC, and reported results | 2015-005181-33 | Safety and Immunogenicity Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) versus Tetanus Toxoid, Reduced Diphtheria Toxoid and ... | bad-data | |
| Trial is outside EEC, and reported results | 2015-005182-23 | Immunogenicity and Safety of the Inactivated Poliomyelitis Vaccine (IMOVAX Polio™) Administered at 2, 3, and 4 Months of Age and Followed by a Booster Dose at 18 Months of age in Healthy Infants in Ch... | bad-data | |
| Trial is outside EEC, and reported results | 2015-005183-42 | Immunogenicity and Safety of Fractional Doses of Sanofi Pasteur’s Inactivated Poliomyelitis Vaccine (IMOVAX Polio™) Administered Intradermally versus Full Doses of Inactivated Poliomyelitis Vaccine (I... | bad-data | |
| Trial is outside EEC, and reported results | 2015-005184-16 | Immunogenicity and Safety of Fractional Booster Dose of sanofi pasteur’s Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intradermally versus Full Booster Dose of Inactivated Poliomyelit... | bad-data | |
| Trial is outside EEC, and reported results | 2015-005185-34 | Safety study of IMOVAX Polio in selected cities in China, an observational post marketing study | bad-data | |
| Trial is outside EEC, and reported results | 2015-005186-23 | Large scale safety study of IMOVAX Polio in selected cities in China, an observational post marketing study | bad-data | |
| Trial is outside EEC, and reported results | 2015-005187-42 | Immunogenicity and Safety of the SP059 Given Subcutaneously as a Three-Dose Primary and Booster Vaccination in Infants in Japan | bad-data | |
| Trial is outside EEC, and reported results | 2015-005188-17 | Immunogenicity and Safety of different sequential schedules of Inactivated Poliomyelitis Vaccine (IMOVAX Polio®) followed by Oral Poliomyelitis Vaccine in Healthy Infants in China versus Oral Poliomye... | bad-data | |
| Trial is outside EEC, and reported results | 2015-005189-48 | Safety and Immunogenicity of Sanofi Pasteur Meningococcal (Groups A and C) Polysaccharide Vaccine versus Lanzhou Institute of Biological Products Meningococcal (Groups A and C) Polysaccharide Vaccine ... | bad-data | |
| Trial is outside EEC, and reported results | 2015-005190-21 | Immunogenicity and Safety of ADACEL Polio (TdcP-IPV Vaccine) Administered at 6 to 8 Years of Age as a Fifth Dose (Pre-School Booster) in Healthy Children in Taiwan | bad-data | |
| Trial is outside EEC, and reported results | 2015-005191-18 | Immunogenicity and Safety of Sanofi Pasteur’s AVAXIM 80U Pediatric Vaccine Administered in Healthy Adolescents, Children and Toddlers in People’s Republic of China Followed by a Booster Dose 6 Months ... | bad-data | |
| Trial is outside EEC, and reported results | 2015-005192-24 | Immunogenicity and Safety of AVAXIM™ 80U-Pediatric Administered Alone or Concomitantly with TRIMOVAX™ in 12-13 Months old Healthy Hepatitis A Seronegative Turkish Children | bad-data | |
| Trial is outside EEC, and reported results | 2015-005193-38 | A Controlled Study of the Safety and Immunogenicity of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children | bad-data | |
| Trial is outside EEC, and reported results | 2015-005194-20 | Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free in Comparison with the Reference Purified Vero Rabies Vaccine in Post-exposure Use in Healthy Subjects in China | bad-data | |
| Trial is outside EEC, and reported results | 2015-005195-22 | Immunogenicity and Safety of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine Given in Japanese Subjects | bad-data | |
| Trial is outside EEC, and reported results | 2015-005196-24 | Three-, Five-, and Ten-Year Data on the Long-Term Immunogenicity of Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) i... | bad-data | |
| Trial is outside EEC, and reported results | 2015-005197-38 | Six-Month, One-Year, Three-Year, Five-Year and Ten-Year Data on the Long-Term Immunogenicity of Td-mIPV, Tdap-vIPV, Td, aP and Tdap in Adolescents and Adults | bad-data | |
| Trial is outside EEC, and reported results | 2015-005293-38 | Immunogenicity and Safety of the sanofi pasteur’s DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™) versus sanofi pasteur’s DTacP-IPV Combined Vaccine (TETRAXIM™) given simultaneously at separate sites wi... | bad-data | |
| Trial is outside EEC, and reported results | 2015-005337-45 | Immunogenicity and Safety of a Booster Dose of Polysaccharide Pneumococcal vaccine (Pneumo 23®) in 12 to 18 Months-Old Children Primed with Three Doses of Pneumococcal Conjugate Vaccine (Prevnar®) in ... | bad-data | |
| Trial is outside EEC, and reported results | 2015-005348-33 | Immunogenicity and safety of Sanofi Pasteur’s DTaP-IPV combined vaccine (TETRAXIM™) given as a three-dose primary vaccination in South Korean healthy infants, as compared to commercially available DTa... | bad-data | |
| Trial is outside EEC, and reported results | 2015-005352-10 | Immunogenicity and Safety of the Aventis Pasteur DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™) Given as a Three-Dose Primary Vaccination at 2, 4 and 6 Months of Age and Followed by a Booster Dose at 1... | bad-data | |
| Trial is outside EEC, and reported results | 2015-005353-12 | Immunogenicity and Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™) Given as a Three-Dose Primary Vaccination at 2, 3 and 4 Months of Age or 3, 4 and 5 Months of Age and followed by a Boost... | bad-data | |
| Trial is outside EEC, and reported results | 2015-005354-35 | Immunogenicity and Safety of the Aventis Pasteur DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™), Given as a Three-Dose Primary Vaccination at 6, 10, and 14 Weeks of Age and Followed by a Booster Dose a... | bad-data | |
| Trial is outside EEC, and reported results | 2015-005403-87 | Immunogenicity and Safety of the sanofi pasteur’s DTacP-IPV Combined Vaccine (TETRAXIM™) given as a booster dose at 4 to 6 years of life in children previously vaccinated with PENTAXIM™ in the study E... | bad-data | |
| Trial is outside EEC, and reported results | 2015-005404-29 | Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM®) Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China | bad-data | |
| Trial is outside EEC, and reported results | 2015-005589-43 | Safety and immunogenicity of Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis (ADACEL™) Vaccine compared to Component Pertussis Vaccine and Diphtheria and Tetanus Toxoids Adso... | bad-data | |
| Trial is outside EEC, and reported results | 2015-005590-20 | Safety Among Adolescents and Adults of Revaccination with Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 4 to 5 Years After a Previous Dose | bad-data | |
| Trial is outside EEC, and reported results | 2015-005627-84 | A pivotal open label, two-arm, multi-center trial to evaluate the safety and immunogenicity of a single dose of Adacel® vaccine in persons 10 to <11 years of age with the intent to extend the licensur... | bad-data | |
| Trial is outside EEC, and reported results | 2015-005628-25 | Immunogenicity and Safety of The tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (SP306) as a Booster in Japanese Adolescents | bad-data | |
| Trial is outside EEC, and reported results | 2015-005629-38 | Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents | bad-data | |
| Trial is partly outside EEC, and reported results | 2015-005789-42 | Randomized, Double-blind, Placebo-controlled, Dose escalation, Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients with Type 2 Diabetes Mellitus Not Adequately... | 2020-01-27 | bad-data |
| Trial is outside EEC, and reported results | 2015-005842-69 | Immune Responses in Adults to Revaccination with Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 10 Years After a Previous Dose | bad-data | |
| Trial is outside EEC, and reported results | 2015-005843-15 | One-, Three-, Five-, Eight- and Ten-Year Data on the Long- Term Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) in Adults and Adolescents | bad-data | |
| Trial is outside EEC, and reported results | 2015-005844-32 | One-, Three-, Five- and Ten-Year Data on the Long-Term Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) in Adolescents 11–14 Years of Age | bad-data | |
| Trial is outside EEC, and reported results | 2015-005845-30 | One-, Three-, Five-, and Ten-Year Data on the Long-Term Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) in Adults and Adolescents (11-64 yea... | bad-data | |
| Trial is partly outside EEC | 2016-000301-37 | Open label, Two Cohort (with and without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients with Gaucher Disease Type 1 and Type 3 | bad-data | |
| Reported results | 2016-000464-42 | A Prospective, Open-label, Interventional Phase IIIb Clinical Trial to Investigate the Effectiveness of an Additional Course of Alemtuzumab in Relapsing Remitting Multiple Sclerosis Patients After 2 C... | 2019-05-28 | due-trials |
| Reported results | 2016-000629-38 | A Randomized, Double-blind, Placebo-controlled Parallel Arm Dose Titration Study to Assess the Effects of SAR407899 in Patients with Microvascular Angina (MVA) and/or Persistent Stable Angina despite ... | 2018-07-23 | due-trials |
| Reported results | 2016-000657-12 | Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients with Early-stage Parkinson's Disease ... | 2021-05-27 | due-trials |
| Reported results | 2016-000749-30 | Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers 12 to 23 Months of Age | 2017-10-26 | due-trials |
| Trial is partly outside EEC, and reported results | 2016-000942-77 | A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Avalglucosidase Alfa (neoGAA, GZ402666) and Alglucosidase Alf... | 2023-05-31 | bad-data |
| Reported results | 2016-001028-80 | Efficacy and safety of SAR156597 in the treatment of diffuse cutaneous Systemic Sclerosis (dcSSc): A randomized, double-blind, placebo-controlled, 24-week, proof of concept study | 2019-04-01 | due-trials |
| Reported results | 2016-001328-77 | A 26-Week Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study to Assess the Safety and Efficacy of SAR425899 in Patients with Type 2 Diabetes Mellitus | 2017-12-27 | due-trials |
| Trial is partly outside EEC, and reported results | 2016-001463-36 | ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX | 2021-11-01 | bad-data |
| Trial is partly outside EEC, and reported results | 2016-001464-11 | ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX | 2021-07-14 | bad-data |
| Trial is partly outside EEC, and reported results | 2016-001607-23 | A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Children 6 to <12 Years of Age with Uncontrolled Persistent Asthma | 2020-08-26 | bad-data |
| Reported results | 2016-001800-49 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients with Type 2 Diabetes Mellitus Who ... | 2019-03-22 | due-trials |
| Reported results | 2016-001801-17 | A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin compared to Glimepiride or Place... | 2019-09-06 | due-trials |
| Reported results | 2016-001803-22 | A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin compared to Empagliflozin, and Placebo in Patients with Type 2 Di... | 2019-05-16 | due-trials |
| Reported results | 2016-001804-43 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Who Have Inadequate Glyc... | 2019-09-27 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-001857-42 | A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr... | 2020-09-07 | bad-data |
| Reported results | 2016-001962-27 | Open-label Phase 2 study evaluating efficacy and safety of SAR566658 treatment in patients with CA6 positive metastatic Triple Negative Breast Cancer | 2018-09-07 | due-trials |
| Trial is outside EEC, and reported results | 2016-001963-35 | A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents | bad-data | |
| Trial is outside EEC, and reported results | 2016-001964-13 | Regulatory Post-Marketing Surveillance (PMS) Study for AVAXIM 160U (Hepatitis A Vaccine) | bad-data | |
| Trial is outside EEC, and reported results | 2016-002089-29 | Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP-T Combined Vaccine Given at 6, 10, and 14 Weeks of Age in Infants in India Who Previously Received a Dose of Hepatitis B Vaccine at Bir... | bad-data | |
| Reported results Terminated | 2016-002739-14 | Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients with Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-... | 2017-11-14 | due-trials |
| Reported results | 2016-002826-35 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to a Sulfonylurea alone or in combination with Metformin in... | 2019-04-30 | due-trials |
| Trial is outside EEC, and reported results | 2016-002873-36 | Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP-T Combined Vaccine at 2, 4, and 6 Months of Age versus Sanofi Pasteur's DTaP-IPV//PRP~T Combined Vaccine at 2, 4, and 6 Months of Age +... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2016-003097-41 | A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination with Pomalidomide and Low-dose Dexamethasone versus Pomalidomide and Low-dose Dexamethasone in Patie... | 2023-11-01 | bad-data |
| Trial is partly outside EEC | 2016-003100-30 | A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclerosis... | 2020-10-26 | bad-data |
| Trial is outside EEC, and reported results | 2016-003444-37 | Bacillus clausii in the treatment of acute community–acquired diarrhea among Latin American children (cadiLAc) | bad-data | |
| Trial is partly outside EEC, and reported results | 2016-003475-21 | An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of Avalglucosidase Alfa (NeoGAA, GZ402666) in Patients with Infantile-onset Pompe Disease Tre... | bad-data | |
| Trial is partly outside EEC, and reported results | 2016-004087-19 | ATLAS-PPX trial: an open-label, multinational, switching study to describe the efficacy and safety of fitusiran prophylaxis in hemophilia A and B patients previously receiving factor or bypassing agen... | 2022-03-25 | bad-data |
| Reported results | 2016-004556-30 | A Multicenter, Randomized, Double-blind, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of a New Formulation of Zenon (Ezetimibe/Rosuvastatin Fixed Dose Combination) in Patients ... | 2021-03-04 | due-trials |
| Reported results | 2016-004763-40 | Immunogenicity and Safety of Quadrivalent Influenza Vaccine (VaxigripTetra™) in Pregnant Women | 2018-06-14 | due-trials |
| Reported results | 2016-004889-26 | A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Mellitus and Moder... | 2019-10-25 | due-trials |
| Reported results | 2016-004906-32 | A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Mellitus and Sever... | 2019-12-11 | due-trials |
| Trial is outside EEC, and reported results | 2016-005165-31 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Comparative Study to Assess the Efficacy and Safety of Spores of Enterogermina in Combination with Oral Rehydration Therapy... | bad-data | |
| Reported results | 2017-000091-28 | Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog®/NovoRapid® in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine, with a 6-month Safety Extension P... | 2019-01-12 | due-trials |
| Reported results | 2017-000092-84 | A 26-week, Randomized, Open-label, Parallel-group Comparison of SAR341402 Mix 70/30 to NovoMix®30 in Adult Patients with Diabetes Mellitus Using Pre-mix Insulin Analogs | 2021-03-08 | due-trials |
| Trial is outside EEC, and reported results | 2017-000230-62 | A Phase III study of M071754 - A single-blind study in patients with infantile spasms. | bad-data | |
| Trial is outside EEC, and reported results | 2017-000239-15 | An open-label, uncontrolled 4-week study to assess the safety, efficacy and pharmacokinetics of Allegra® (dry syrup formulation) 15 mg or 30 mg twice daily in pediatric patients with perennial allergi... | bad-data | |
| Trial is outside EEC, and reported results | 2017-000251-74 | An open-label, uncontrolled 4-week study to assess the safety, efficacy and pharmacokinetics of Allegra® (dry syrup formulation) 15 mg or 30 mg twice daily in pediatric patients with atopic dermatitis... | bad-data | |
| Trial is outside EEC, and reported results | 2017-000611-17 | A Long term study of M071754 - A open-label study in patients with infantile spasms. | bad-data | |
| Exempt | 2017-000690-36 | A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamics Evaluation of Amcenestrant (SAR439859), Administered Orally as Monotherapy, then in Combination with Other AntiCancer ... | 2022-08-16 | not-yet-due |
| Trial is outside EEC, and reported results | 2017-001044-35 | Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine in Children Aged 6 months to 17 Years | bad-data | |
| Listed as ongoing, but also has a completion date | 2017-001431-39 | A Phase 1/2 study to evaluate safety, pharmacokinetics and efficacy of isatuximab in combination with REGN2810 in patients with relapsed/refractory multiple myeloma I/II. fázisú vizsgálat a REGN281... | 2023-04-05 | bad-data |
| Trial is partly outside EEC, and reported results | 2017-001903-60 | A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Label Treatment Period to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents with Heterozygous Familial... | 2022-08-05 | bad-data |
| Other | 2017-001940-37 | Randomized, Open Label, Multicenter Study Assessing The Clinical Benefit Of Isatuximab Combined With Carfilzomib (Kyprolis®) And Dexamethasone Versus Carfilzomib With Dexamethasone In Patients With R... | not-yet-due | |
| Reported results | 2017-001993-40 | Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered as a Booster Dose in Children Vaccinated 3 Years Earlier as Toddlers | 2018-09-10 | due-trials |
| Trial is partly outside EEC, and reported results | 2017-002134-23 | Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients with Moderate to Severe Asthma who Completed the TRAVERSE-LTS12551Clinical Trial | 2022-02-18 | bad-data |
| Ongoing | 2017-002238-21 | A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination with Bortezomib (Velcade®), Lenalidomide (Revlimid®) and Dexamethasone versu... | not-yet-due | |
| Trial is partly outside EEC, and reported results | 2017-002297-39 | An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents with Homozygous Familial Hypercholesterolemia | 2020-02-17 | bad-data |
| Reported results | 2017-002309-36 | A randomized, double-blind, parallel-group, 2-treatment multiple dose study to assess the intestinal, metabolic and cardiovascular effects of an 8 weeks treatment with sotagliflozin QD as compared wit... | 2019-04-18 | due-trials |
| Reported results | 2017-002644-32 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Cardi... | 2020-07-08 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-002756-91 | A 12-week randomized, controlled trial to compare TOUJEO® and TRESIBA® in terms of glucose values in target range and variability during continuous glucose monitoring in patients with type 1 diabetes ... | 2021-09-16 | bad-data |
| Reported results | 2017-002774-39 | An Exploratory, Randomized, Double-blind, Placebo-controlled, Parallel Arm Trial of the Safety and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Patients with Worsening Heart Fa... | 2019-08-17 | due-trials |
| Ongoing, reported early | 2017-002846-61 | A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination with REGN2810 or Isatuximab alone, in Patients with Advanced ... | not-yet-due | |
| Reported results | 2017-002954-35 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular ... | 2020-12-10 | due-trials |
| Reported results | 2017-002956-10 | A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients with Type 2 Dia... | 2020-11-17 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-002988-18 | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis | 2020-11-24 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-002989-42 | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with polymyalgia rheumatica | 2021-05-19 | bad-data |
| Reported results | 2017-003289-29 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12-week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500 and the Coadministration of ... | 2019-08-07 | due-trials |
| Reported results | 2017-003290-34 | A randomized, double-blind, placebo-controlled, parallel-group, Proof-of-Concept (PoC) study to assess the efficacy, safety and tolerability of SAR440340, in patients with moderate-to-severe chronic o... | 2020-02-21 | due-trials |
| Trial is partly outside EEC | 2017-003317-25 | One year study to evaluate the long-term safety and tolerability of dupilumab in pediatric patients with asthma who participated in a previous dupilumab asthma clinical study | bad-data | |
| Reported results | 2017-003370-13 | A multi-center open-label parallel group randomized controlled trial to compare iGlarLixi versus premixed insulin in patients with type 2 diabetes who have failed to achieve glycemic control with basa... | 2020-07-20 | due-trials |
| Reported results | 2017-003510-16 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabetes ... | 2020-06-05 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-003538-10 | A PHASE 3, PIVOTAL, OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WHO HAVE A RECENT HISTORY OF BLOOD TRANSFUSION | 2021-09-15 | bad-data |
| Exempt | 2017-004012-19 | An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocyto... | not-yet-due | |
| Reported results | 2017-004069-29 | Persistence of Anti-HBs Antibodies at 6 to 7 Years of Age in Subjects Having Received a DTaP-IPV-HB-PRP~T Hexavalent Vaccine at 3, 5, and 11 to 12 Months of Age, and Evaluation of Their Immune Memory ... | 2019-06-20 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-004084-12 | Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at risk of Rapidly Progres... | 2021-08-03 | bad-data |
| Exempt, with results Terminated | 2017-004148-39 | An open-label, first-in-human, dose escalation study of SAR440234 administered as single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell ... | not-yet-due | |
| Trial is outside EEC, and reported results | 2017-004181-10 | Immunogenicity and Safety of Sanofi Pasteur’s DTaP IPV HB PRP~T Combined Vaccine Given as a Three-Dose Primary Series at 2, 3, 4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months o... | bad-data | |
| Other | 2017-004520-30 | Immunogenicity and safety study of an investigational quadrivalent meningococcal conjugate vaccine in infants and toddlers when administered using a 1+1 schedule in a National Immunization Schedule ha... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2017-004731-36 | Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers in Eu... | 2023-05-17 | bad-data |
| Trial is outside EEC, and reported results | 2017-004977-15 | Safety and Immunogenicity of a 3-Dose Schedule of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2018-000390-67 | A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab (SAR650984) in combination with atezolizumab or isatuximab alone in patients with advanc... | 2022-05-11 | bad-data |
| Completed, but no date, and reported results Terminated | 2018-001355-12 | Phase IV, randomized, double-blind, multicenter, placebo-controlled clinical trial to evaluate the efficacy and the safety of enterogermina (Bacillus clausii) in treating patients with small intestina... | bad-data | |
| Trial is outside EEC, and reported results | 2018-001468-48 | Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults Aged 10 to 55 Years | bad-data | |
| Trial is outside EEC, and reported results | 2018-001470-18 | Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine | bad-data | |
| Trial is outside EEC, and reported results | 2018-001471-20 | Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children 2 to 9 Years of Age | bad-data | |
| Trial is outside EEC, and reported results | 2018-001472-38 | Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Other Pediatric Vaccines in Healthy Toddlers | bad-data | |
| Trial is outside EEC | 2018-001473-24 | Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers | bad-data | |
| Listed as ongoing, but also has a completion date | 2018-001953-28 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstruct... | 2023-05-02 | bad-data |
| Listed as ongoing, but also has a completion date | 2018-001954-91 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstruct... | 2023-12-01 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-002261-19 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor PRN1008 in Moderate to Severe Pemphigus | 2021-12-17 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-002442-37 | A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab in combination with other anti-cancer therapies in participants with lymphoma | 2022-11-08 | bad-data |
| Trial is partly outside EEC, and reported results | 2018-002697-45 | Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years o... | 2023-05-26 | bad-data |
| Trial is partly outside EEC | 2018-002880-25 | ATLAS-OLE: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX | bad-data | |
| Reported results | 2018-003790-10 | Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix® or NeisVac-C® in Healthy Toddlers 12 to 23 Months of Age | 2020-10-14 | due-trials |
| Trial is outside EEC, and reported results | 2018-003838-32 | Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (SP0173) in Healthy Adolescents, Adults, and Older Adults | bad-data | |
| Reported results | 2018-003927-12 | A Phase 2b dose-finding study for SAR442168, a Bruton's tyrosine kinase inhibitor, in participants with relapsing multiple sclerosis | 2020-01-20 | due-trials |
| Reported results | 2018-004055-20 | Immunogenicity and Safety of a Purified Vero Rabies Vaccine – Serum Free in Comparison with Verorab® and Imovax® Rabies, in a Simulated Rabies Post-exposure Regimen in Healthy Adults in France | 2021-07-01 | due-trials |
| Trial is outside EEC, and reported results | 2018-004519-31 | Randomized, placebo-controlled, clinical trial to evaluate the efficacy of probiotic Bacillus clausii in the treatment of pediatric patients with irritable bowel syndrome | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2018-004593-98 | An Open Label Randomized Phase 2 Trial of SAR439859, Versus Endocrine Monotherapy as per Physician’s Choice in Patients with Estrogen Receptor-positive, HER2-Negative Locally Advanced or Metastatic Br... | 2022-08-16 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-004705-26 | A randomized double blind placebo controlled study evaluating the effect of dupilumab on sleep in adult patients with moderate to severe atopic dermatitis | 2021-10-06 | bad-data |
| Trial is outside EEC, and reported results | 2018-004707-40 | Verorab® immunogenicity and safety after a one week, 4-site, intradermal (ID) post-exposure prophylaxis regimen (4-4-4-0-0) followed by a one visit, 4-site, ID booster at five years. | bad-data | |
| Trial is outside EEC, and reported results | 2018-004708-21 | Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine Given as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and in HIV-Exposed Uninfected Infan... | bad-data | |
| Ongoing | 2018-004731-76 | Long-term extension safety and efficacy study of SAR442168 in participants with relapsing multiple sclerosis | not-yet-due | |
| Trial is outside EEC, and reported results | 2018-005026-39 | Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 months to 17 Years of Age | bad-data | |
| Reported results Terminated | 2019-000064-21 | A randomized, open-label, active comparator, 2-arm, prospective study to assess the glycosphingolipid clearance and clinical benefits of agalsidase beta (Fabrazyme®) in male patients with classic Fabr... | 2020-07-24 | due-trials |
| Completed, but no date, and reported results Terminated | 2019-000065-20 | A randomized, open-label, active comparator, 2-arm, prospective study to assess the glycosphingolipid clearance and clinical effects of switching to agalsidase beta (Fabrazyme®) versus continuing on m... | bad-data | |
| Reported results | 2019-000655-14 | Immunogenicity and Safety of a High-Dose Quadrivalent Influenza Vaccine Administered by the Intramuscular Route in Subjects 60 Years of Age and Older | 2020-06-05 | due-trials |
| Trial is partly outside EEC | 2019-000679-18 | ATLAS-PEDS: An open-label, multinational study of fitusiran prophylaxis in male pediatric subjects aged 1 to less than 12 years with hemophilia A or B | bad-data | |
| Trial is outside EEC | 2019-000973-22 | Immunogenicity and Safety of a Purified Vero Rabies Vaccine – Serum Free in Comparison with Verorab® and Imovax® Rabies, in a Pre-exposure Regimen in Both Pediatric and Adult Populations and a Single ... | bad-data | |
| Trial is outside EEC, and reported results | 2019-000993-44 | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Singapore | bad-data | |
| Trial is outside EEC, and reported results | 2019-000994-22 | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico | bad-data | |
| Listed as ongoing, but also has a completion date | 2019-001273-81 | Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic Non-Squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors | 2023-12-20 | bad-data |
| Reported results Terminated | 2019-001401-25 | Relative Effectiveness of a High-Dose Quadrivalent Influenza Vaccine versus a Standard-Dose Quadrivalent Influenza Vaccine in Subjects 65 Years of Age and Older | 2022-04-01 | due-trials |
| Reported results | 2019-002015-26 | Phase 2 window study of two dose levels of SAR439859 (SERD) versus letrozole in newly diagnosed preoperative post-menopausal patients with ER positive, HER2 negative primary breast cancer | 2021-05-28 | due-trials |
| Trial is partly outside EEC, and reported results | 2019-002023-15 | Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; ... | 2022-02-03 | bad-data |
| Trial is outside EEC, and reported results | 2019-002218-38 | Safety of a Quadrivalent Influenza Vaccine (VaxigripTetraTM) in Subjects Aged 6 Months and Older in Vietnam | bad-data | |
| Ongoing | 2019-002375-34 | A multicenter, multinational, randomized, double-blind, placebo-controlled study to assess the efficacy, pharmacodynamics, pharmacokinetics, safety, and tolerability of venglustat in late-onset GM2 ga... | not-yet-due | |
| Ongoing | 2019-002585-12 | Immunogenicity and Safety of DTaP-IPV-HB-PRP~T Combined Vaccine Given at 3, 5, and 12 Monhs of Age Concomitantly or Sequentially 4CMenB Vaccine in Italian Infants Immunogenicità e sicurezza del vac... | not-yet-due | |
| Trial is outside EEC, and reported results | 2019-003135-36 | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially with Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia | bad-data | |
| Trial is outside EEC, and reported results | 2019-003136-23 | Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially with Adacel® in Healthy Subjects Aged 9 to 60 Years in the Philippines | bad-data | |
| Ongoing | 2019-003139-47 | A Phase 3 randomized, open label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smolde... | not-yet-due | |
| Reported results Terminated | 2019-003751-10 | A randomized, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy, safety, and tolerability of SAR440340 (anti-IL-33 mAb) in patients with moderate-to-severe asthma Estudio... | 2021-01-13 | due-trials |
| Reported results | 2019-003774-41 | A randomized, double blind, placebo-controlled, multi-center, parallel group study to evaluate the efficacy and safety of dupilumab in patients with prurigo nodularis who are inadequately controlled o... | 2022-02-03 | due-trials |
| Trial is partly outside EEC | 2019-003775-19 | Master protocol of three randomized, double-blind, placebo-controlled, multi center, parallel-group studies of dupilumab in patients with chronic spontaneous urticaria (CSU) who remain symptomatic des... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2019-003801-90 | A randomized, double blind, placebo-controlled, multi-center, parallel group study to evaluate the efficacy and safety of dupilumab in patients with prurigo nodularis who are inadequately controlled o... | 2021-11-22 | bad-data |
| Ongoing | 2019-003914-15 | Open-label, single-arm trial to evaluate antitumor activity, safety, and pharmacokinetics of SAR408701 used in combination with ramucirumab in metastatic, non-squamous, non–small-cell lung cancer (NSQ... | not-yet-due | |
| Trial is outside EEC, and reported results | 2019-004008-36 | Immunogenicity and Safety of a Purified Vero Rabies Vaccine– Serum Free (VRVg) Assessed with the Institut Pasteur du Cambodge (IPC: 2-2-2-0-0) and the Thai Red Cross (TRC: 2-2-2-0-2) Intradermal Regim... | bad-data | |
| Completed, reported early | 2019-004080-43 | Suliqua® (iGlarLixi) in Participants uncontrolled on basal insulin to Evaluate the change of time in target Range By using Continuous Glucose Monitoring Suliqua® (iGlarLixi) alkalmazása bázisinzuli... | 2023-04-04 | not-yet-due |
| Reported results Terminated | 2019-004138-41 | A phase IV randomized, double-blind, 3-treatment, 3-period, 6-sequence crossover clinical trial to assess the efficacy and safety of hyoscine butylbromide co-administered with ibuprofen compared to pl... | 2020-11-20 | due-trials |
| Completed, but no date, and reported results Terminated | 2019-004154-28 | A Phase 1b/2 study to evaluate the safety, pharmacokinetics, and preliminary efficacy of isatuximab (SAR650984) in patients awaiting kidney transplantation Estudio de fase 1b/2 para evaluar la segu... | bad-data | |
| Reported results | 2019-004394-10 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered... | 2022-09-22 | due-trials |
| Trial is outside EEC, and reported results | 2019-004459-35 | A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers | bad-data | |
| Trial is outside EEC | 2019-004460-22 | Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers | bad-data | |
| Trial is outside EEC, and reported results | 2019-004461-41 | Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults | bad-data | |
| Listed as ongoing, but also has a completion date | 2019-004647-74 | Randomized, double blind, placebo controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of lung function, mucus plugging and other lung imaging parameters in ... | 2023-08-21 | bad-data |
| Trial is outside EEC | 2019-004721-24 | Efficacy, Immunogenicity, and Safety of High-Dose Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months through 35 Months of Age | bad-data | |
| Listed as ongoing, but also has a completion date | 2020-000035-50 | Randomized, open-label, Phase 2 study of SAR408701 combined with pembrolizumab and pembrolizumab alone in patients with CEACAM5 and PD-L1 positive advanced/metastatic non-squamous non–small-cell lung ... | 2023-12-20 | bad-data |
| Trial is outside EEC, and reported results | 2020-000314-15 | Open label exploratory study to evaluate the effect of dupilumab on skin barrier function in patients with moderate to severe atopic dermatitis | bad-data | |
| Listed as ongoing, but also has a completion date | 2020-000511-77 | A randomized, double-blind, placebo-controlled, parallel-group study of the safety, tolerability, pharmacokinetics, and therapeutic efficacy of SAR441344 in adult patients with primary Sjögren’s synd... | 2024-02-01 | bad-data |
| Ongoing | 2020-000637-41 | A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis | not-yet-due | |
| Ongoing | 2020-000644-55 | A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis | not-yet-due | |
| Other | 2020-000645-14 | A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS) | not-yet-due | |
| Other | 2020-000647-30 | A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis | not-yet-due | |
| Reported results Terminated | 2020-000970-10 | Phase III, randomized, double blind, parallel groups, clinical trial to evaluate the efficacy and safety of Bacillus clausii versus placebo in the prevention of antibiotic associated diarrhea (AAD) in... | 2022-01-11 | due-trials |
| Reported results | 2020-001162-12 | An adaptive phase 2/3, randomized, double-blind, placebo-controlled, study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19 Estudio adaptativo de fase 2/3, aleator... | 2020-09-02 | due-trials |
| Other | 2020-001217-20 | A phase 4, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of the effect of dupilumab on sleep disturbance in patients with uncontrolled persistent asthma | not-yet-due | |
| Trial is outside EEC, and reported results | 2020-001223-14 | Imovax® Rabies and VERORAB® Immunogenicity and Safety after One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Intradermal or Intramuscular... | bad-data | |
| Reported results Terminated | 2020-001270-29 | An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19 | 2020-06-25 | due-trials |
| Other | 2020-001518-40 | Open-label exploratory study to evaluate the effect of dupilumab on skin barrier function in pediatric patients with moderate to severe atopic dermatitis | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2020-001665-37 | Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix®, and When Administered Alone or Concomitantly with 9vHPV and Tdap-IPV Vaccines in Healthy Adolescents... | 2022-05-11 | bad-data |
| Ongoing | 2020-001818-38 | Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderat... | not-yet-due | |
| Ongoing | 2020-001819-24 | Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderat... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2020-001824-33 | A randomized, multicenter, double-blind phase 3 study of amcenestrant SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer wh... | 2023-05-26 | bad-data |
| Ongoing | 2020-002063-60 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults an... | not-yet-due | |
| Trial is outside EEC | 2020-002601-26 | A randomized, double-blind, placebo-controlled, multi-center, parallel-group study to evaluate the efficacy, safety and pharmacokinetics of dupilumab compared to placebo in Japanese patients with atop... | bad-data | |
| Trial is outside EEC, and reported results | 2020-002854-25 | Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1-, 2-, or 3-Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years after the Last... | bad-data | |
| Exempt | 2020-003024-16 | Phase 1-2 trial evaluating anti-TGFß agent (SAR439459) or pomalidomide in combination with isatuximab and dexamethasone in relapsed or refractory multiple myeloma (RRMM) Sperimentazione di fase 1-... | 2023-01-26 | not-yet-due |
| Listed as ongoing, but also has a completion date | 2020-003096-18 | Open-label, multi-cohort, Phase 2 trial, evaluating the efficacy and safety of SAR408701 in patients with CEACAM5-positive advanced solid tumors Estudio de Fase 2, abierto, de múltiples cohortes pa... | 2023-12-20 | bad-data |
| Listed as ongoing, but also has a completion date | 2020-003117-35 | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of dupilumab in patients with uncontrolled, chronic rhinosinusitis without nasal polyposis (CRSsNP) | 2024-01-29 | bad-data |
| Reported results Terminated | 2020-003120-17 | A 3-part study to evaluate the efficacy and safety of venglustat in combination with Cerezyme in adult and pediatric patients with Gaucher disease Type 3 (GD3) with open-label long-term treatment | 2021-06-10 | due-trials |
| Ongoing | 2020-003370-41 | Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines with AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-... | not-yet-due | |
| Reported results | 2020-003542-36 | A multi-center, exploratory study to assess dupilumab effect on pruritus neuro-mechanisms in patients with atopic dermatitis | 2022-08-17 | due-trials |
| Completed, reported early | 2020-003756-33 | A randomized, double-blind, placebo-controlled, multi-center, parallel-group study of dupilumab in patients with chronic inducible cold urticaria who remain symptomatic despite the use of H1-antihista... | 2023-04-20 | not-yet-due |
| Exempt | 2020-003880-24 | A multicenter, open-label, non-randomized, Phase 1b/2 study to evaluate the safety, pharmacokinetics,and efficacy of subcutaneous isatuximab in adults with warm autoimmune hemolytic anemia | 2023-06-26 | not-yet-due |
| Ongoing | 2020-004006-54 | A Phase 2, multicenter, open-label, non-randomized, proof-of-concept study evaluating the efficacy, safety, and tolerability of BIVV020 in adults with chronic inflammatory demyelinating polyneuropathy... | not-yet-due | |
| Reported results | 2020-004162-18 | A multicenter, Phase 2a, open-label, non-randomized study evaluating the efficacy, safety, and tolerability of BIVV020 in adults with persistent/chronic immune thrombocytopenia (ITP) | 2023-02-07 | due-trials |
| Trial is outside EEC | 2020-004341-36 | Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, and Children in India and Healthy Adolescents and Children in the Republic ... | bad-data | |
| Reported results | 2020-004400-34 | Multicenter, open-label, extension study to characterize the long-term efficacy and safety of early versus delayed treatment with venglustat (GZ/SAR402671) in patients at risk of rapidly progressive a... | 2021-07-13 | due-trials |
| Trial is partly outside EEC | 2020-004686-39 | An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of avalglucosidase alfa in Treatment naïve Pediatric Participants ... | bad-data | |
| Listed as ongoing, but also has a completion date | 2020-004703-14 | A randomized, double-blind, placebo controlled, proof of concept study assessing the efficacy and safety of the RIPK1-inhibitor SAR443122 in patients with moderate to severe subacute or discoid/chroni... | 2023-06-26 | bad-data |
| Ongoing | 2020-004785-19 | A Phase 2, double-blind, randomized, placebo-controlled study assessing efficacy and safety of SAR441344, a CD40L-antagonist monoclonal antibody, in participants with relapsing multiple sclerosis | not-yet-due | |
| Ongoing | 2020-005331-78 | A Phase 2 non-randomized, open-label, multi-cohort, multi center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants... | not-yet-due | |
| Exempt | 2020-005332-30 | A Phase 1/2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR- 707) combined with cemiplimab for the treatment of participants with advance... | not-yet-due | |
| Other | 2020-005566-33 | Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to Stamaril® in Adults | not-yet-due | |
| Ongoing | 2021-000010-41 | A multi-cohort, randomized, Phase 2, open-label study to assess the preliminary efficacy, safety, and pharmacokinetics of BIVV020 (SAR445088) for prevention and treatment of antibody-mediated rejecti... | not-yet-due | |
| Ongoing, reported early | 2021-000104-38 | A Phase IIIb, Open-label, Multi-center Study to Evaluate the Immunogenicity and Safety of a Booster Dose and Describe the Immune Persistence of MenACYW Conjugate Vaccine with 5- and/or 10-year Booster... | not-yet-due | |
| Reported results Terminated | 2021-000398-10 | A randomized, multicenter, double-blind, Phase 3 study of amcenestrant (SAR439859) versus tamoxifen for the treatment of patients with hormone receptor-positive, human epidermal growth factor 2-negati... | 2022-10-13 | due-trials |
| Listed as ongoing, but also has a completion date | 2021-000725-28 | A Phase IIb, Randomised, Double Blind, Placebo Controlled, Parallel Group, Multicentre Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopi... | 2024-02-21 | bad-data |
| Ongoing | 2021-000829-27 | A randomized, double-blind, head-to-head comparison of dupilumab versus omalizumab in severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and comorbid asthma patients | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2021-001567-25 | Efficacy and safety of SAR441344 in the treatment of Systemic Lupus Erythematosus: A randomized, double blind, placebo-controlled, Phase 2, proof of concept study | 2022-04-07 | bad-data |
| Ongoing | 2021-001654-65 | A Phase 2a, open label, two-part study to evaluate the mechanism of action of itepekimab (anti-IL-33 mAb) on airway inflammation in patients with chronic obstructive pulmonary disease (COPD) | not-yet-due | |
| Ongoing | 2021-001671-16 | A multicenter, open-label, Phase IIb study to evaluate the efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia | not-yet-due | |
| Completed, report not yet due | 2021-001704-15 | A Phase 2, randomized, double-blind, placebo-controlled, multicenter proof-of-concept study evaluating efficacy and safety of rilzabrutinib in adult patients with moderate-to-severe atopic dermatitis ... | 2023-06-23 | not-yet-due |
| Ongoing | 2021-001967-26 | Open-label study of tusamitamab ravtansine (SAR408701) in combination with ramucirumab in participants previously treated for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma with CE... | not-yet-due | |
| Not reported Terminated | 2021-002105-99 | A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants... | 2022-10-27 | due-trials |
| Trial is outside EEC, and reported results | 2021-002146-33 | Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Toddlers and Infants | bad-data | |
| Completed, but no date Terminated | 2021-002150-91 | Phase 2 non-randomized, open-label, multi-cohort, multicenter study assessing the clinical benefit of SAR444245 (THOR-707) with or without other anticancer therapies for the treatment of adults and ad... | bad-data | |
| Ongoing | 2021-002181-41 | A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants... | not-yet-due | |
| Ongoing | 2021-002320-20 | A randomized, open-label, parallel-group, 18-month Phase 3 study to evaluate the effect of venglustat compared with usual standard of care on left ventricular mass index in participants with Fabry dis... | not-yet-due | |
| Other | 2021-002344-73 | A long-term extension study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in adult participants with moderate to severe atopic dermatitis who participated in ... | not-yet-due | |
| Other | 2021-002350-90 | A randomized, double-blind, placebo-controlled, 12 month Phase 3 study to evaluate the effect of venglustat on neuropathic and abdominal pain in male and female adults with Fabry disease who are treat... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2021-002485-41 | A randomized, Phase 3, open label study evaluating subcutaneous versus intravenous administration of isatuximab in combination with pomalidomide and dexamethasone in adult patients with relapsed and/o... | 2023-02-17 | bad-data |
| Ongoing | 2021-002490-26 | A randomized, double-blind, placebo-controlled, parallel-group, 12 week Proof-of-Concept (PoC) study to assess the efficacy, safety, and tolerability of rilzabrutinib in participants with moderate-to-... | not-yet-due | |
| No trial status on register | 2021-002590-26 | A French multicenter Phase 4 open label extension study of long term safety and efficacy in patients with Pompe disease who previously participated in avalglucosidase development studies in France | bad-data | |
| Ongoing | 2021-002609-93 | A randomized, double-blind, placebo-controlled, multicenter, dose-ranging Phase 2 study of rilzabrutinib followed by an open-label extension phase in patients with moderate-to-severe chronic spontaneo... | not-yet-due | |
| Trial is outside EEC | 2021-003070-31 | Safety and Immunogenicity of an Investigational Multicomponent Meningococcal Group B Vaccine in Adults, Adolescents, Toddlers, and Infants | bad-data | |
| Trial is outside EEC, and reported results | 2021-003176-14 | An Open-label, Single-arm, Multi-center Study to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients with Non-Hodgkin’s ... | bad-data | |
| Completed, report not yet due | 2021-003711-25 | A 24-Week, Single-Arm, Phase 4 Clinical Study to Evaluate the Efficacy and Safety of Switching to iGlarLixi in People with Type 2 Diabetes Mellitus Uncontrolled on Once or Twice Daily Premixed Insulin... | 2023-07-21 | not-yet-due |
| Reported results | 2021-003898-59 | A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of tolebrutinib (SAR442168) in adults with generalized myasthenia gravis (MG) | 2023-02-21 | due-trials |
| Ongoing | 2021-003903-16 | A Randomized, Double-Blind, Placebo controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients with Uncontrolled Moderate to Severe Asthma | not-yet-due | |
| Trial is outside EEC, and reported results | 2021-004047-25 | A Single Arm, Prospective, Open-label, Multi-center Study to Evaluate Efficacy and Safety in Chinese Patients with Infantile-Onset Pompe Disease with One Year Alglucosidase Alfa Treatment | bad-data | |
| Listed as ongoing, but also has a completion date | 2021-004156-42 | A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants with amyotrophic lateral sclerosis, followed by an ope... | 2024-02-14 | bad-data |
| Exempt | 2021-004287-98 | An open-label, first-in-human, dose-escalation/expansion study of SAR443579 administered as single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia (R/R AML... | not-yet-due | |
| Ongoing | 2021-004315-76 | Master protocol of two randomized, double blind, placebo-controlled, multi-center, parallel group studies to evaluate the efficacy and safety of dupilumab in adult patients with chronic pruritus of un... | not-yet-due | |
| Ongoing | 2021-004423-32 | Open-label, Phase 2 study, evaluating the efficacy and safety of tusamitamab ravtansine in non-squamous non-small-cell lung cancer (NSQ NSCLC) participants with negative or moderate CEACAM5 expression... | not-yet-due | |
| Ongoing | 2021-005353-82 | Prospective study to assess with Continuous Glucose Monitoring (CGM) the efficacy and safety of switching to insulin glargine 300 U/ml from insulin glargine 100 U/ml in Type 2 Diabetes (T2DM) patients... | not-yet-due | |
| Other | 2021-005402-10 | A phase 3, multicenter, multinational, randomized, double-blind, double-dummy, active-comparator study to evaluate the efficacy and safety of venglustat in adult and pediatric patients with Gaucher di... | not-yet-due | |
| Trial is outside EEC, and reported results | 2021-005552-11 | A Long-term Study to Evaluate Growth and Development Outcomes in Patients With Infantile-Onset Pompe Disease Who Are Receiving Alglucosidase Alfa. | bad-data | |
| Ongoing | 2021-006069-39 | A Randomized, Double-Blind, Parallel-Group Clinical Trial to Assess the Efficacy of Essentiale on Hepatic Steatosis Added to Standard of Care Versus Placebo Added to Standard of Care, in Non-Alcoholic... | not-yet-due | |
| Trial is outside EEC, and reported results | 2021-006686-37 | Immunogenicity and Safety of a DTwP-HepB-Hib-IPV (SHAN6™) Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers in Thailand | bad-data | |
| Ongoing | 2022-000049-34 | A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open label long-te... | not-yet-due | |
| Ongoing | 2022-000065-41 | A randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to assess the efficacy, safety, and tolerability of subcutaneous amlitelimab in adult participants with moderate to-s... | not-yet-due | |
| Other | 2022-000099-20 | A Phase IIIb randomized open-label study of nirsevimab (versus no intervention) in preventing hospitalizations due to respiratory syncytial virus in infants (HARMONIE) | not-yet-due | |
| Completed, report not yet due Terminated | 2022-000576-19 | Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine Compared with Egg-Based Standard-Dose Quadrivalent Influenza Vaccine in Children 3 to 8 Years of Age. | 2023-12-07 | not-yet-due |
| Listed as ongoing, but also has a completion date | 2022-000577-11 | Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years | 2023-10-27 | bad-data |
| Ongoing | 2022-001177-31 | An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy without first line therapeutic plasma exchange in adults with immune-medi... | not-yet-due | |
| Exempt | 2022-001239-95 | A Phase 1/2, open label, first-in-human, dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR445877 administered as mono... | not-yet-due | |
| Trial is outside EEC, and reported results | 2022-001441-21 | Immunogenicity and Safety of the Quadrivalent Inactivated Split-Virion Influenza Vaccine in Participants 6 Months of age and Older in India | bad-data | |
| Completed, report not yet due | 2022-001485-35 | A 24-Week, Multicenter, Randomized, Open-Label, Parallel-Group Trial Comparing the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve ... | 2023-06-30 | not-yet-due |
| Ongoing | 2022-002253-26 | International, multi-center, open-label, treatment extension study in patients with multiple myeloma who are still benefitting from isatuximab-based therapy following completion of a Phase 1, 2, or 3 ... | not-yet-due | |
| Trial is outside EEC, and reported results | 2022-002375-11 | A Randomized, Double Blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Persistent Asthma | bad-data | |
| Trial is outside EEC, and reported results | 2022-002452-40 | Immune Response to Pertussis after Vaccination with a Tdap-IPV Booster Vaccine in Children in the Republic of South Africa: Effect of Homologous and Heterologous Pertussis Vaccination Priming Backgrou... | bad-data | |
| Ongoing | 2022-002767-30 | A randomized, Phase 2, open label study evaluating subcutaneous administration of isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory mul... | not-yet-due | |
| Completed, but no date Terminated | 2022-002959-18 | An open label, two-arm, Phase 2a study to evaluate the effect of rilzabrutinib (PRN1008/SAR444671) on safety and disease activity in patients with IgG4-related disease Estudio de fase IIa, abierto ... | bad-data | |
| Exempt | 2022-003500-33 | An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects with Advanced or Metastatic Solid Tumors Estudi... | not-yet-due | |
| Trial is outside EEC, and reported results | 2022-003923-17 | Safety and Immunogenicity Study of Full Schedule (3-Dose of Shan6™) or Shan6™-Shan5®-Shan6™ Versus the Licensed Vaccine Shan5® With bOPV (bivalent oral polio vaccine) and IPV (inactivated poliomyeliti... | bad-data | |
| Trial is outside EEC, and reported results | 2023-000624-11 | A Phase 4, open label, safety and efficacy study of Fabrazyme® (agalsidase beta) as enzyme replacement therapy in Chinese participants with Fabry Disease | bad-data | |
| Trial is outside EEC | 2023-000924-13 | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity study to assess Pentavalent Meningococcal ABCYW Vaccine formulations in Adults (18 to 25 years of age) and Adolescents (10 to 17 years ... | bad-data | |
| Trial is outside EEC, and reported results | 2023-001027-16 | A Phase 4, single-arm, open-label safety and efficacy study of Aldurazyme® (laronidase) as enzyme replacement therapy in participants with Mucopolysaccharidosis I (MPS I) in China | bad-data | |
| Trial is outside EEC | 2024-000041-27 | A single arm, prospective, open label, multicenter study to evaluate efficacy and safety of one-year maximum dosage in Chinese label of imiglucerase treatment in Chinese patients who are diagnosed as ... | bad-data |